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Ageing	 and	 diabetes	 are	 two	 major	 healthcare	 concerns	 that	 used	 to	 be	 regarded	 as	
problems	 of	 the	Western	world	 but	 are	 now	of	 increasing	 concern	 in	 developing	 nations.	
Treating	elderly	patients	with	diabetes	poses	issues	for	clinicians	due	to	often	complex,	pre-
existing	 drug	 regimes.	 Research	 targeted	 at	 the	 development	 of	 novel	 drugs	 that	 have	
multiple	 effects	 on	 diabetes	 could	 go	 some	way	 towards	 reducing	 polypharmacy	 in	 these	
patients.	 Here	 I	 present	 evidence	 that	 the	 oral	 Jak1/3	 inhibitor,	 baricitinib,	 has	 effects	 on	
multiple	aspects	of	diabetes.	Baricitinib	has	been	suggested	to	be	a	strong	anti-inflammatory	
given	the	role	 Jak	plays	 in	 transducing	cytokine	signals	 to	elicit	 immune	cell	activation	and	
maturation.	 Baricitinib	 was	 found	 to	 reduce	 urinary	 albumin	 to	 creatinine	 ratio	 and	
mesangial	 expansion	 in	 mice	 on	 an	 experimental	 high-fat	 diet	 with	 a	 diabetic	 metabolic	
profile	when	 compared	with	 naïve,	 non-diabetic	mice.	 This	 reduction	 in	 renal	 impairment	
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our	health.	 Increasing	 longevity	 in	western	populations	has	caused	changes	to	the	kinds	of	
diseases	that	are	causing	morbidity	and	mortality	in	our	societies.	In	order	to	keep	ahead	of	
the	new	developments	related	to	the	changing	western	lifestyle	we	must	innovate	and	keep	
at	 the	 forefront	 of	 our	 minds	 the	 needs	 of	 the	 people	 we	 are	 trying	 to	 help.	 The	multi-
factorial	nature	of	the	task	ahead	means	that	it	must	be	attacked	on	several	fronts,	whether	
that	 is	 pharmacological,	 societal	 or	 clinical.	 Another	 consideration	 as	 pharmacologists	 and	
clinicians	is	whether	to	treat	the	disease	as	it	presents	or	the	underlying	cause	of	disease,	so	
diabetes,	visceral	obesity	or	 the	pathology	of	ageing	 itself.	 Indeed,	 it	 is	clear	not	 just	 from	
now,	but	also	from	our	previous	experience,	that	 if	we	are	to	truly	make	 in-roads	 into	this	









Age	 is	 associated	with	 increased	 hospitalisation	with	 23%	of	 the	 global	 burden	 of	 disease	
being	 associated	 with	 those	 aged	 over	 65	 (Prince	 et	 al.,	 2015)	 despite	 those	 in	 this	 age	




















and	especially	chronic	obesity	 into	old	age	 increases	 insulin	resistance	with	ageing	(Ahima,	
2009),	so	ageing	is	known	to	have	a	contributory	role	in	the	development	of	diabetes.	
	
Diabetes	has	 long	been	 considered	 the	 leading	 cause	of	 end-stage	 renal	disease	 (ESRD)	 in	
developed	 economies	 (Ghaderian	 et	 al.,	 2015).	 Its	 management,	 especially	 in	 the	 elderly	
poses	 a	 challenge	 to	nephrologists	 (Abdel-Rahman	et	 al.,	 2012,	 Joseph	&	Friedman,	2009)	
and	 is	 a	 leading	 cause	 of	 death	 among	 diabetic	 patients	 after	with	 cardiovascular	 disease	
(CVD)	 (Zhu	 et	 al.,	 2015).	 Additionally,	 it	 is	 a	 great	 cause	 of	morbidity	 and	 chronic	 pain	 is	
commonly	 encountered	 by	 clinicians	 in	 patients	 with	 diabetic	 nephropathy	 (DN)	 (Galer,	
Gianas	&	 Jensen,	 2000),	 potentially	 leading	 to	 further	 complications	 due	 to	 the	 impact	 of	











ageing,	 these	 are	 changes	 in	 cellular	 communication,	 mitochondrial	 dysfunction,	 loss	 of	
nutrient	 sensing,	 deregulation	 of	 proteostasis,	 epigenetic	 changes,	 telomere	 attrition,	
genomic	 instability,	cellular	senescence	and	stem	cell	exhaustion.	 	These	aspects	of	ageing	
all	play	a	role	in	the	overall	changes	we	see	in	a	cell	or	organism.	The	basis	of	many	of	the	








1β	 (IL-1	β),	 IL-6,	 IL-8	and	 tumour	necrosis	 factor-α	 (TNFα)	but	 it	would	be	 true	 to	say	 that	
almost	 all	 common	cytokines	have	been	noted	 to	be	elevated	 in	advanced	age.	 There	are	
many	 causes	 of	 the	 up-regulated	 cytokine	 profile	 in	 ageing	 which	 have	 been	 discussed,	
insufficient	 resolution	 of	 acute	 inflammatory	 insults	 (Tabas,	 2010)	 and	 a	 link	 to	 cellular	
senescence	 (Sikora,	 Scapagnini	 &	 Barbagallo.	 2010)	 have	 both	 been	 postulated	 as	 prime	
causes	 of	 this	 observation.	 The	 downstream	 effects	 of	 chronic	 inflammation	 are	 wide	





described	 by	 Lopez-Otin	 et	 al.,	 for	 example	 ‘immunosenescence’.	 Deeks	 (2011)	 describes	
immunosenescence	 as	 a	 case	 where	 chronic	 immune	 activation	 results	 in	 a	 weakened	
immune	 system	 in	 old	 age	 due	 to	 senescence	 among	 immune	 cells.	 Mitochondrial	
dysfunction	may	play	a	causative	role	in	the	activation	of	the	inflammasome	in	ageing	cells	
(Salminen	et	al.,	2012).	The	role	of	inflammation	in	the	pathogenesis	of	diabetes	also	links	to	
deregulation	 of	 nutrient	 sensing	 (Hotamisligil	 &	 Erbay,	 2008).	 Indeed,	 inflammation	 is	 the	
perfect	 aspect	 of	 ageing	 to	 show	 the	 truly	 multifactorial	 nature	 of	 this	 disease	 (if	 it	 can	
indeed	be	referred	to	as	that).	This	is	highlighted	by	the	2012	paper	by	Jenny,	‘Inflammation	
in	Aging:	Cause,	Effect,	or	Both?’	this	paper	poses	a	‘chicken-and-egg’	question	in	relation	to	









(Kroemer,	 Galluzzi	 &	 Brenner,	 2007).	 Mitochondrial	 degeneration	 can	 be	 prevented	 by	
mitophagy	 and	 its	 role	 in	 clearing	 defective	 mitochondria	 from	 the	 cell,	 in	 turn	 inducing	
biogenesis	of	new	mitochondria.	 Indeed,	deregulation	of	mitophagy	may	play	a	role	 in	the	













into	 two	key	 categories	 these	being,	 protein	 folding	 and	protein	degradation.	 Incorrect	or	
damaged	proteins	are	often	the	result	of	a	genetic	mutation,	however	post-transcriptional	





protein	 degradation	 is	 mainly	 focused	 on	 ubiquination	 and	 the	 proteasome.	 Chaperonins	
play	 a	 key	 role	 in	 the	 correction	 of	 incorrectly	 folded	 proteins	 by	 ‘encouraging’	 re-folding	
into	 a	 conformationally	 active	 shape,	 restoring	 function.	 Lower	 levels	 of	 protein	 folding	
correction	 have	 been	 shown	 in	 advancing	 age	 (Calderwood,	Murshid	&	 Prince,	 2009)	 and	
failure	of	this	system	has	been	implicated	in	several	ageing	related	diseases	(Powers	et	al.,	
2009).	 The	 second	 branch	 of	 this	 system	 relates	 to	 proteolysis	 or	 the	 degradation	 of	
incorrect	or	damaged	proteins,	this	is	often	the	result	of	a	failure	of	chaperonins	to	correct	a	
folding	 error	 or	 a	 genetic	mutation,	 however	 post-transcriptional	 damage	 by	 oxidation	 or	




Proteolysis	 has	 two	 main	 aspects,	 the	 autophagy-lysosomal	 system	 and	 the	 ubiquitin-
proteasome	system.	Reduced	efficacies	in	both	proteolytic	systems	have	been	implicated	in	
ageing	 and	ageing	 related	diseases	 (Rubinsztein,	Mariño	&	Kroemer,	 2011).	 The	ubiquitin-
proteasome	 is	 shown	 below	 in	 figure	 1.2.	 This	 system	 is	 not	 only	 used	 to	 dispose	 of	
damaged	 proteins	 but	 also	 as	 a	 regular	 part	 of	 proteome	maintenance	 and	 regulation	 of	
signalling	by	degrading	a	signalling	protein,	therefore	reducing	signal	transduction	(Ley	et	al.,	





Figure	 1.2.	 The	 ubiquitin-proteasome	 system	 tagging	 a	 protein	 for	 degradation	 allowing	 it	 to	 enter	




The	 second	arm	of	proteolysis	 is	 the	autophagy-lysosomal,	 this	 system	 is	used	 to	degrade	
large	 amounts	 of	 protein	 and	 sometimes,	 whole	 organelles	 like,	 as	 seen	 in	 figure	 1.3,	 a	
mitochondrion.	 In	 this	 process	 an	 internal	 vesicle	 (autophagosome)	 is	 formed	 around	 the	
item	 or	 items	 to	 be	 degraded,	 then	 endosomes	 and	 lysosomes	 fuse	 with	 the	












When	 we	 consider	 nutrient	 sensing	 in	 a	 general	 sense,	 insulin	 is	 one	 of	 the	 primary	
hormones	 associated	 with	 energy	 states.	 The	 insulin/insulin-like	 growth	 factor	 (IGF-1)	
signalling	pathway	(IIS)	has	been	implicated	in	the	activation	of	pathways	relating	to	ageing	
and	 indeed	 knockdown	 and	 knockout	 models	 of	 IIS	 depletion	 have	 shown	 increased	







Insulin	 and	 IGF-1	 signal	 through	 membrane	 bound	 receptors	 to	 elicit	 changes	 to	 cellular	
processes	and	gene	transcription,	this	pathway	is	shown	below	in	figure	1.4.	The	diagram	of	
the	 IIS	 pathway	 shown	 in	 figure	 1.4	 illustrates	 the	 interplay	 between	 insulin	 and	 IGF-1	
signalling.	 It	 is	 seen	 in	 this	 illustration	 that	activation	of	 the	 receptors	 for	either	 insulin	or	
IGF-1	results	 in	a	similar	change	to	cellular	energetics	and	transcription.	Most	 interestingly	
for	 ageing	 is	 the	 ability	 of	 this	 pathway	 to	 induce	 cellular	 survival,	 proliferation	 and	
senescence	 via	 the	 activation	 of	 protein	 kinase	 B	 (AKT)	 or	 through	 interaction	 with	 the	
RAS/RAF	pathway.	 If	 insulin	activates	pathways	associated	with	an	ageing	phenotype,	such	
as	cellular	senescence	pathways	then	elevated	levels	are	detrimental	to	ageing	(van	Heemst,	
2010).	 Indeed,	 this	 also	 lends	 support	 to	 the	 idea	 that	 a	 reduction	 in	 caloric	 intake	 and	











the	decondensation	of	chromosomal	deoxyribose	nucleic	acids	 (DNA)	 the	G1	checkpoint	 is	
reached	whereby	if	a	cell	is	not	viable	then	it	enters	the	so-called	‘G0’	phase.	Its	association	
with	 ageing	has	 been	 shown	by	 the	 increase	 in	 senescent	 cells	within	 aged	mice	 to	 ≈17%	
compared	with	≈8%	in	young	mice	(Wang	et	al.,	2009).	Cells	in	senescence	have	been	shown	
to	 have	 a	 unique	 combination	 of	 signals	 that	 they	 secrete	 including	 an	 increased	 pro-










Stem	 cells	 are	 undifferentiated,	 multipotent	 cells	 capable	 of	 replacing	 other,	 terminally	
differentiated	cells	within	the	body.	Stem	cells	have	differing	degrees	of	plasticity	regarding	
the	 number	 of	 different	 cell	 types	 they	 can	 differentiate	 into.	Depending	 on	 the	 cell	 type	
that	 needs	 replacing,	 the	 size	 of	 the	 population	 available	 to	 replace	 it	 may	 vary.	 The	
exhaustion	of	 stem	cell	populations	has	been	noted	 in	a	 large	number	of	cell	populations,	
including	the	immune	system	with	a	phenomenon	known	as	‘immunosenescence’	reported	
by	 Shaw	et	 al.,	 (2010).	 The	process	 of	 immunosenescence	 is	 associated	with	 a	 number	 of	
changes	 within	 the	 aged	 body	 relating	 to	 telomere	 attrition,	 cellular	 senescence	 and	
inflammageing.	 The	 constitutive	 activation	 of	 the	 immune	 system	 by	 chronic	 over-
expression	 of	 proinflammatory	 cytokines	 results	 in	 the	 exhaustion	 of	 the	 progenitor	 cells	
within	the	bone	marrow.	The	exhaustion	of	these	stem	cell	populations	results	in	the	loss	of	
functional	mass;	such	as	muscle	mass	due	to	damaged	cells	no	longer	being	replaced	in	old	






Genetic	 and	 genomic	 changes	 are	 seen	 by	 many	 to	 be	 the	 ‘root	 cause’	 of	 many	 of	 the	
hallmarks	of	ageing.	Traditional	models	of	biology	put	the	genome	at	the	centre	of	the	cell	
and	 all	 processes	 thereof,	 however	 the	 delicate	 interplay	 between	 DNA	 and	 protein	 has	
come	 to	 the	 fore	 in	 terms	 of	 our	 thinking.	 Ageing	 associated	 changes	 to	 DNA	 include	
epigenetic	 changes	 (Wilson	 &	 Jones,	 1983)	 which	 are	 only	 possible	 because	 of	 correct	
protein	 folding	 and	 genomic	 stability,	 or	 lack	 thereof	 which	 can	 be	 as	 a	 result	 of	 radical	
attack	(Hongmei	et	al.,	2013).	Telomere	attrition	 is	the	only	remaining	hallmark	associated	
with	 the	 genome,	 this	 appears	 intrinsically	 linked	 to	 ageing	 (Armanios	 et	 al.,	 2009)	 and	
considering	 humans	 lack	 of	 telomerase	 it	 seems	 that	 there	 will	 be	 no	 way	 to	 avoid	 this	
hallmark.	
	
Ultimately	 there	 are	 a	 number	 of	 ways	 to	 categorise	 the	 ‘pathologies’	 that	 result	 from	













overwhelming	majority	 of	 DM	 cases	 can	 be	 divided	 into	 two	main	 types,	 type	 1	 diabetes	
mellitus	 (T1DM),	originally	 called	 insulin-dependent	or	 juvenile	onset	and	T2DM,	originally	











blood	glucose	sample,	 further	 to	 this;	 fasting	blood	glucose	test	may	be	carried	out	and	 is	
usually	 found	 to	 be	 elevated	 also	 and	 a	 deranged	 oral	 glucose	 tolerance	 test	 (OGTT)	 is	
common.	 Other	 tests	 may	 reveal	 the	 effects	 of	 the	 disease	 on	 the	 body	 including	
proteinuria,	ketoacidosis,	ketonuria,	peripheral	numbness	and	visual	disturbances.	The	gold	





DM	has	multiple	 forms	 that	 each	 have	 subtly	 different	 causes,	mechanisms	 of	 action	 and	
therefore	treatments.	The	most	common	forms	are	T1DM	and	T2DM,	however	there	is	also	
gestational	diabetes,	a	 temporary	decrease	 in	 insulin	sensitivity	 in	pregnant	 females	which	




Type	1	diabetes	mellitus	(T1DM)	 is	characterised	by	depletion	 in	the	amount	of	 insulin	the	
body	can	make	and	therefore	lower	insulin	levels	are	found	in	the	blood	stream	(Heise	et	al.,	
2004).	T1DM	 is	generally	accepted,	 to	be	as	a	 result	of	autoimmune	destruction	of	 insulin	
expressing	 β-cells	 in	 the	 Islets	 of	 Langerhans	 of	 the	 pancreas	 (Yoon	 &	 Jun,	 2005).	 The	
mechanism	of	this	is	well	known,	what	is	less	well	known	is	what	triggers	this	mechanism	to	





the	hormone	 insulin.	Reductions	 in	 insulin	sensitivity	result	 in	changes	to	the	ability	of	 the	
body	to	maintain	glucose	homeostasis	(maintenance	of	blood	glucose	levels)	and	as	a	result,	
patients	 with	 T2DM	 usually	 have	 elevated	 blood	 glucose	 levels	 when	 uncontrolled.	 The	
mechanisms	of	resistance	are	many	not	always	fully	understood	and	will	be	explored	later	in	
this	 chapter.	 Patients	 with	 T2DM	 will	 commonly	 be	 encouraged	 to	 make	 lifestyle	








patients	 are	 some	 of	 the	most	 heavily	medicated	 patents	 as	 drugs	 for	 co-morbidities	 are	





Correct	 differential	 diagnosis	 of	 DM	 is	 clearly	 important	 due	 to	 the	 differing	 treatments	
associated	with	each	branch	of	 the	disease.	Diagnosis	of	a	 type	of	diabetes	 is	difficult	and	
often	an	imperfect	science	as	patients	may	present	with	very	similar	symptoms	or	develop	
one	type	as	a	result	of	another	e.g.	T2DM	following	gestational	diabetes.	BMJ	Best	Practice	
states	 that	 differentiating	 between	 T1DM	 and	 T2DM	 is	 often	 made	 on	 the	 initial	
presentation	of	the	patient;	they	are	usually	under	35,	not	obese	and	may	well	have	a	family	
history	of	T1DM.	Tests	may	 include	 the	presence	of	ketones	 in	 the	urine,	which	 is	 seldom	
seen	in	T2DM,	but	common	in	T1DM	(Newton	and	Raskin,	2004).	Additional	tests	would	be	










or	 site	 of	 use	 in	 the	 body	 via	 the	 blood	 in	 the	 form	of	 glucose.	 For	 the	 body	 to	maintain	
blood	glucose	concentrations	it	must	have	mechanisms	for	both	withdrawing	and	depositing	
glucose	 into	 the	 circulation.	 The	 mechanisms	 of	 glucose	 homeostasis	 are	 controlled	 by	
endocrine	hormones,	which	 are	mainly	 released	by	 the	pancreas;	 the	main	hormones	 are	
insulin	 and	 glucagon.	 The	 pancreas	 has	 both	 exocrine	 and	 endocrine	 functions;	 the	
endocrine	tissues	of	the	pancreas	are	referred	to	as	the	Islets	of	Langerhans	and	contain	two	






Insulin	 is	released	from	β-cells	 in	the	 Islets	of	Langerhans	of	the	pancreas.	 It	 is	responsible	
for	lowering	blood	glucose	and	is	released	in	response	to	increased	glucose	concentrations	




ATP	act	 to	 inhibit	K+	 channels	on	 the	 surface	membrane	of	 the	 cell	 causing	depolarisation	
and	 therefore	 opening	 Ca2+	 channels	 allowing	 an	 influx	 of	 Ca2+,	 inducing	 exocytosis	 of	
vesicles	containing	insulin.	
	









paracrine	 signalling	 from	 each	 other	 as	 well	 as	 other	metabolic	 hormones	 present	 in	 the	
islets.	
	
Figure	 1.7.	Glucagon	 release	 in	 response	 to	 decreasing	 blood	 glucose	 concentration	 (adapted	 from	
Wollheim	&	Maechler,	2015).	
	
The	 hormones	 insulin	 and	 glucagon	 have	 effects	 on	most	 cell	 types	 in	 the	 body	 but	 their	
main	 targets	 are	muscle,	 fat	 and	 liver.	 Insulin	 acts	 to	 lower	 blood	 glucose,	 it	 does	 this	 by	
withdrawing	 glucose	 from	 the	 circulation	and	 this	 takes	different	 forms	depending	on	 the	
target	cell.	In	the	liver	for	example,	insulin	inhibits	gluconeogenesis	and	glycogenolysis	while	
promoting	glycolysis	and	glycogenesis	(Newsholme	&	Leech,	1983).	In	the	muscle,	glycolysis	
is	 promoted	 by	 activation	 of	 glucose-6-phosphatase	 (Newsholme	 &	 Leech,	 1983)	 and	




reaction	 to	 that	 of	 muscle	 in	 that	 it	 increases	 the	 number	 of	 GLUT4	 transporters	 on	 its	
surface	 membrane	 to	 withdraw	 glucose	 from	 the	 blood	 stream	 (Kersten,	 2001).	 Another	
effect	of	insulin	on	adipose	tissue	is	to	promote	lipogensis	through	up	regulation	of	a	series	
of	 promoters	 known	 as	 sterol	 regulatory	 element–binding	 proteins	 (SREBPs)	 (Horton,	
Goldstein	 &	 Brown,	 2002).	 In	 the	 fasting	 state,	 where	 there	 is	 low	 glucose	 availability,	
glucagon	 prevails	 and	 the	 reverse	 of	 these	 processes	 are	 carried	 out,	 such	 as	 hepatic	
gluconeogenesis,	 glycogenolysis	 and	 inhibition	 of	 glycolysis	 (plus	 a	 shift	 towards	 oxidative	
phosphorylation)	 and	 glycogenesis	 (Hüttemann	 et	 al.,	 2007).	 The	 mechanisms	 associated	







Diabetes	 and	 specifically	 T2DM	 is	 an	 interruption	 of	 the	 normal	 mechanisms	 of	 glucose	
homeostasis	within	the	body,	it	is	highly	multifactorial	and	some	facets	of	its	pathology	are	
poorly	understood.	It	is	essentially	characterised	as	an	inability	of	the	body	to	properly	sense	
and	 react	 to	 changes	 in	 insulin	 levels	 in	 the	 blood.	 All	 effects	 of	 insulin	 on	 target	 cells	
mentioned	earlier	in	this	section	are	depressed	due	to	lower	signal	transduction.	The	leading	
theory	 relating	 to	 induction	 of	 insulin	 resistance	 in	 T2DM	 is	 the	 action	 of	 fat	 deposits,	
especially	in	key	metabolic	organs,	the	liver	(Tiikkainen	et	al.,		2004)	and	the	muscle	(Khan	et	
al.,	 2015).	 Fat	 specific	 hormones	 and	 cytokines	 are	 believed	 to	 be	 key	 regulators	 and	
promoters	 of	 the	 insulin	 resistance	 associated	with	 HFD	 feeding	 and	 T2DM	with	 IL-6	 and	
TNFα	being	 first	 in	 consideration	 for	 this	 (Hotamisligil	 et	 al.,	 1995,	 Kern	 et	 al.,	 2001).	 The	
specific	 role	 of	 these	 cytokines	 in	 promoting	 insulin	 resistance	 is	 poorly	 understood	
(Hotamisligil	et	al.,	1995)	but	it	may	play	a	role	in	fat	remodelling	(Harford	et	al.,	2011)	and	
this	may	contribute	to	the	mechanical	failures	in	insulin	resistance.	Additional	roles	of	insulin	













from	CVD	 in	 T2DM	patients	 (Morrish	 et	 al.,	 2001).	 CVD	has	 a	 strong	 link	 to	 dyslipidaemia	
(Pöss	 et	 al.,	 2011),	which	 according	 to	 the	American	Diabetic	 Association	 affected	 65%	of	
diabetic	patients	between	2009	and	2012.	 The	 second	biggest	 killer	of	diabetic	patients	 is	
complications	of	the	renal	system	(Zhu	et	al.,	2015).	Diabetic	nephropathy	(DN)	is	a	complex	
renal	disorder	associated	with	 renal	 failure	and	 so	ultimately	high	mortality	 (Ghaderian	et	











1980).	 DN	 is	 often	 diagnosed,	 secondary	 to	 diabetic	 retinopathy	 as	 there	 are	 strong	
associations	between	the	two	and	visual	symptoms	are	usually	easier	to	see	in	retinopathy	
(Lee	et	 al.,	 2014).	 Patients	will	 sometimes	present	with	 foamy	urine,	 fatigue	and	 sacral	or	
pitting	 ankle	 oedema	 although	 the	 condition	 is	 commonly	 discovered	 before	
hypoalbuminaemia	 leads	 to	 these	 symptoms.	 Clinical	 findings	 include,	 proteinuria	 and	
hypertension	with	definitive	diagnosis	made	by	 renal	biopsy	 showing	histological	 changes.	
Initial	 diagnosis	 is	 a	 urine	 albumin	 of	 30-300	 mg	 urinary	 albumin	 per	 24	 hours	 (Evans	 &	
Capell,	 2000).	 This	 progresses	 over	 time	 to	 become	 more	 severe	 and	 being	 related	 to	 a	






Kidney	 damage	 with	 normal	












In	 DN	 additional	 measures	 are	 used	 to	 track	 this	 progression	 the	 very	 lowest	 levels	 of	
microalbuminuria	 (between	 15	 and	 300	 μg/min)	 are	 found	 in	 stage	 3.	 Higher	 levels	 (>0.5	
g/24hr)	of	proteinuria	are	found	in	stage	4	where	there	is	a	rapid	decline	in	GFR	and	in	stage	




the	disease	and	are	missed	until	 the	disease	becomes	more	serious,	 this	means	 that	early	




glomerular	 basement	 membrane	 (BM),	 found	 in	 the	 glomerulus.	 The	 Bowman’s	 capsule	
surrounds	the	glomerulus;	this	is	an	arrangement	of	epithelial	cells	that	receive	the	filtrated	
blood	 from	 the	 glomerulus.	 Blood	 is	 force	 filtered	 into	 the	Bowman’s	 capsule	by	 the	high	
pressure	 of	 afferent	 arteriole	 and	 the	 narrowing	 of	 the	 lumen	 in	 the	 efferent	 arteriole,	
meaning	 there	 is	 a	 high	 filtration	 pressure,	 forcing	 the	 contents	 of	 the	 blood	 into	 the	





the	 membranes	 of	 the	 endothelial	 cells,	 making	 a	 filtration	 barrier	 to	 erythrocytes	 and	
proteins	(Singh	et	al.,	2007).	The	second	barrier	is	the	basement	membrane,	this	is	primarily	
made	 up	 of	 laminin	 and	 collagen	 (Suh	&	Miner.	 2013)	 and	 acts	 to	 filter	 solutes	 from	 the	
blood	 that	are	 smaller	 than	1μm	or	around	10kDa.	The	 final	barrier	 is	 the	podocyte	 layer;	
this	can	be	seen	in	figure	1.9	as	the	overarching	cell	on	the	glomerular	side	of	the	basement	
membrane.	The	podocytes	help	 to	maintain	 the	 integrity	of	 the	basement	membrane	and	







Figure	 1.9.	 Illustration	 of	 the	 glomerular	 filtration	 barrier	 and	 basement	membrane	 (adapted	 from	
Suh	&	Miner,	2013).	
	
In	 DN	 there	 is	 a	 loss	 of	 this	 fine	 filtration	 structure,	 caused	 by	 several	 changes	 to	 the	
Bowman’s	capsule.	Changes	 in	the	 integrity	of	 the	basement	membrane	can	be	associated	
with	 several	 pathological	 changes;	 mechanical	 stresses	 from	 hypertension	 contribute	 to	
increases	 in	 thickness	 and	 permeability	 (Iversen	 &	 Ofstad,	 1987).	 Inflammation	 results	 in	
changes	in	the	cells	of	the	Bowman’s	capsule	including	vascular	endothelial	(Feener	&	King,	
1996),	mesangial	 (Steffes	 et	 al.,	 1989)	 and	podocyte	 (Susztak	 et	 al.,	 2006)	 cells	while	 also	




Mesangial	 expansion	 is	 known	 to	 have	 a	 big	 part	 to	 play	 in	 the	 pathogenesis	 of	 DN.	
Mesangial	cells	help	to	maintain	the	shape	of	the	‘tuft	of	blood	vessels	in	the	glomerulus	and	
are	 situated	 at	 the	 ‘neck	 of	 this’,	 their	 location	 is	 shown	 in	 figure	 1.10.	 Expansion	 of	 the	












in	 the	 case	 of	 DM	due	 to	 chronic	 higher	 levels	 of	 glucose	 (Ahmed,	 2005).	When	 proteins	
become	 glycated	 this	 often	 changes	 their	 ability	 to	 interact	 with	 other	 proteins	 and	with	
cells.	A	change	in	the	conformation	of	a	protein	of	the	BM	or	glycocalyx	would	result	in	the	
interactions	 it	makes	 in	order	to	physically	 form	a	filtration	barrier	to	break	down,	causing	
	 43	
filtration	 to	 fail	 (Forbes	 et	 al.,	 2003).	 The	 multiplicity	 of	 factors	 that	 cause	 DN	 in	 the	




increases	triglyceride,	 free	fatty	acid	(FFA),	 low-density	 lipoproteins	(LDL),	very-low-density	
lipoproteins	 (VLDL)	and	a	decrease	 in	high-density	 lipoprotein	 (HDL)	 (Goldberg,	2001).	This	
kind	 of	 lipid	 profile	 in	 a	 patient	 suggests	 a	 high	 risk	 of	 CVD	 (Howard	 et	 al.,	 2000).	 The	










regulatory	 proteins,	 an	 overview	 of	 this	 process	 can	 be	 seen	 in	 figure	 1.11.	 Following	
stimulation	 from	 a	 number	 of	 signals,	 such	 as	 increasing	 insulin	 resistance	 and	 cytokines,	
adipocytes	 release	 FFA	 due	 to	 stimulation	 of	 lipoprotein	 lipase	 (LPL).	 These	 enter	 the	
circulation	 and	 are	 withdrawn	 from	 the	 circulation	 by	 hepatocytes,	 which	 express	
apolipoproteins	(Apo).	Apo	is	usually	broken	down	when	produced	unless	bound	to	fat,	the	
increased	presence	of	fat	causes	these	proteins	to	bind	to	fat	and	become	lipoproteins,	like	















The	 Jak/STAT	 pathway	 acts	 as	 part	 of	 cytokine	 signalling	 pathways,	 it	 is	 associated	 with	
signal	transduction	from	cellular	membrane	receptors	to	the	nucleus.	The	Janus	kinase	(Jak)	
family	 were	 discovered	 as	 part	 of	 a	 wide	 screen	 of	 kinases	 performed	 by	Wilkes	 (1989).	
These	cytosolic	proteins	were	found	to	be	non-receptor	kinases	that	associated	with	signal	
transducer	 and	 activator	 of	 transcription	 (STAT)	 proteins	 resulting	 in	 the	 phosphorylation	























then	7	STATs	 that	can	all	 form	dimers	with	each	other	means	 that	 there	 is	a	 large	web	of	
signalling	 rather	 than	 a	 straightforward	 signalling	 pathway.	 The	 total	 number	 of	
combinations	that	can	be	formed	with	activation	of	this	pathway	is	784,	showing	the	huge	
redundancy	 in	 this	 system.	 Although	 is	 it	 true	 that	 the	 Jaks	 do	 not	 all	 associate	with	 the	
same	 receptors	 for	 cytokines,	 figure	 1.13	 shows	 which	 Jaks	 preferentially	 associate	 with	
which	cytokine	receptors.	The	map	in	figure	1.13	is	by	no	means	exhaustive	but	gives	an	idea	
of	the	kind	of	receptors	that	link	to	the	Jak/STAT	pathway	(Murray,	2007).	












In	 figure	 1.14	 is	 illustrated	 the	 kinds	 of	 cytokines	 and	 how	 their	 receptors	 preferentially	








The	 Jak	 family	of	 non-receptor	protein	 tyrosine	 kinases	has	4	members,	 these	being	 Jak1,	
Jak2,	 Tyk2	 and	 Jak3.	 These	 proteins	 associate	 with	 the	 cytosolic	 domains	 of	 activated	
cytokine	 receptor	 dimers,	 resulting	 in	 the	 phosphorylation	 of	 key	 tyrosine	 residues	 in	 the	
‘inactivation	loop’	(Schindler	et	al.,	2007).	The	phosphorylation	of	Jaks	is	mediated	both	by	
the	 association	 of	 Jak	 with	 a	 receptor	 and	 the	 action	 of	 the	 other	 Jak	 bound	 to	 the	
alternative	receptor	subunit	as	both	Jaks	are	responsible	for	phosphorylation	of	each	other.	








tyrosine	 residue	 becomes	 phosphorylated	 (Schindler	 et	 al.,	 2007).	 Another	 key	 domain	 of	
the	 STAT	 protein	 in	 is	 the	 DNA	 Binding	 Domain	 (DBD)	 that	 allows	 for	 association	 with	
enhancer	DNA	sequences.	Upon	activation	by	phosphorylation,	STAT	proteins	associate	with	















B-Cell,	 in	 this	 case,	 both	 cells	 are	 being	 activated	 via	 the	 Jak/STAT	 pathway	 as	 both	 IL-2	
(Bright,	 Kerr	 &	 Sriram,	 1997)	 and	 IL-4	 (Jiang	 H,	 Harris	 M	 &	 Rothman	 P,	 2000)	 receptors	
associate	with	Jaks	to	transduce	their	signal	evoke	changes	in	the	cell.	 In	figure	1.17	the	T-
Cell	 is	 self-activating	 via	 the	 expression	 of	 IL-2	 and	 is	 also	 further	 activating	 the	 B-Cell	 by	
expressing	IL-4,	this	cell	would	a	T-helper	(Th)	cell.	Th-cells	could	be	considered	the	‘cytokine	
	 50	
factories’	 of	 the	 body.	 Th-Cells	 are	 responsible	 for	 the	 activation	 of	 the	 humeral	 immune	
response,	 neutrophils,	 macrophages,	 fibroblasts	 and	 Tc-Cells.	 Th-Cells	 fall	 into	 two	 main	
categories,	 being	 Type-1	 (Th1)	 and	 Type-2	 (Th2)	 (Carter	 &	 Dutton,	 1996).	 The	 primary	
activator	 for	both	Th	and	Tc	cells	 is	 IL-2;	 this	 is	 released	by	Th-Cells	and	activates	all	T-Cell	
types	in	an	autocrine	fashion.	IL-2	binds	to	IL-2	receptors	expressed	on	the	surface	of	T-Cells	
as	 well	 as	 dendritic	 cells	 and	 other	 immune	 targets	 (Boyman	 &	 Sprent,	 2012)	 inducing	
activation	 in	 a	 positive	 feedback	 loop.	 Another	 key	 cytokine	 produced	 by	 Th1	 cells	 is	
Interferon-γ	 (IFNγ);	 this	 activates	 macrophages,	 the	 main	 target	 of	 Th1	 cells	 (Mosser	 &	
Edwards,	2008).	Tc-Cells	express	IL-2	receptors	on	their	surface	and	as	such	are	susceptible	








The	mechanism	of	Jak	 inhibitor	efficacy	 is	poorly	understood	and	there	 is	debate	as	to	the	




activation.	 The	 other	 side	 of	 the	 Jakinib	 story	 is	 the	 idea	 that	 inhibitors	 are	 general	 anti-
inflammatories;	 certainly	 there	 is	 a	 strong	 inflammatory	 component	 of	 in	 RA,	 for	 which	
Jakinibs	 have	 been	 used,	 leading	 credence	 to	 this	 idea.	 There	 are	 a	 number	 of	 papers	
published	 on	 the	 inhibition	 of	 Jaks	 being	 anti-inflammatory	 (Kudlacz	 et	 al.,	 2008)	 or	 Jaks	
playing	a	role	 in	strongly	 inflammatory	diseases	(Gyurkovska	&	Ivanovska,	2015).	 Inhibition	
of	the	Jaks	is	not	uncommon	and	there	are	many	so-called	‘Jakinibs’	in	early	clinical	usage	as	






&	 He,	 2010)	 but	 there	 is	 as	 yet,	 little	 published	 evidence	 of	 studies	 into	 the	 effects	 of	
inhibition	on	 the	severity	of	kidney	disease.	That	which	has	been	published	or	 is	 currently	
being	 investigated	 has	 focused	 on	 diabetic	 kidney	 disease	 (DN)	 (Berthier	 et	 al.,	 2009).	 A	
phase	 II	 clinical	 trial	 recently	 concluded	 in	 the	 USA	 that	 used	 a	 Jak	 1/2	 inhibitor	 called	
baricitinib	 (Eli	 Lilly)	 in	 DN	 patients	 and	 presented	 its	 findings	 at	 the	 2015	meeting	 of	 the	
American	diabetes	association.	This	Phase	two	trial	showed	a	dose	dependent	reduction	in	




Pathway	 inhibition	 is	 postulated	 to	 be	 beneficial	 in	 several	 renal	 pathologies,	 not	 just	
confined	to	a	specific	type	of	injury	(Chuang	&	He,	2010).	Unilateral	uretal	obstruction	(UUO)	
models	 were	 used	 to	 evaluate	 the	 role	 of	 STAT3	 signalling	 on	 renal	 fibrosis	 with	 positive	
results	(Pang	et	al.,	2010,	Kuratsune	et	al.,	2007).	HIV	associated	nephropathy	(Cijiang	He	et	
al.,	 2004)	 and	anti-Thy	1.1	 induced	nephropathy	 (Yanagita	et	 al.,	 2001)	models	have	been	
shown	 to	 have	 an	 element	 of	 Jak/STAT	 signalling	 in	 their	 pathology.	 Finally,	
ischaemia/reperfusion	 induced	acute	 kidney	 injury	 (AKI)	 has	been	postulated	 to	have	as	 a	









• Assess	 the	 feasibility	 of	 using	 an	 animal	model	 of	 ‘artificial	 ageing’	 in	 nephrology	
research	
	









• Explore	 the	 cholesterol	 lowering	 mode	 of	 action	 of	 the	 oral	 Jak1/2	 inhibitor	
‘baricitinib’	
	













and	 2000’s	 this	 model	 become	 increasingly	 popular	 in	 China	 especially	 as	 a	 means	 of	
creating	 an	 ageing	 ‘disease	 model’	 in	 vivo	 (Ho	 et	 al.,	 2003,	 Wei	 et	 al.,	 2005).	 The	
development	of	this	model	was	focused	on	its	 impact	on	the	central	nervous	system	(CNS)	
and	induction	of	behavioural	changes	(Wei	et	al.,	2005).	Studies	attempting	to	elucidate	the	
mechanism	 by	 which	 these	 changes	 in	 behaviour	 were	 induced	 concluded	 that	 DGal	
changed	the	state	of	the	redox	environment,	inducing	oxidative	stress	in	the	brain	(Cui	et	al.,	





inflammation	 (Licastro	et	al.,	2005).	This	chronic	 inflammation	 is	suspected	to	be	 linked	to	
ROS	 and	 other	 radical	 species	 generated	 as	 part	 of	 normal	 inflammation	 and	metabolism	
(Raha	&	Robinson,	2000,	Finkel	&	Holbrook,	2000).	Ageing	in	the	kidney	is	often	considered	
to	be	accelerated	in	the	diseased	state	(Giachelli,	2004,	Ferenbach	&	Bonventre.	2015).	The	




Ageing	 is	 an	 extremely	 complex	multifactorial	 process,	 which	 especially	 in	 humans	 varies	




2009).	 Developed	 nations	 are	 already	 spending	 almost	 four	 times	more	 on	 healthcare	 for	
the	elderly	than	for	the	remaining	population	(Anderson	&	Hussey,	2000).	
	
Renal	 impairment	 increases	 with	 advancing	 age	 and	 certainly	 will	 form	 a	 part	 of	 the	
increased	 burden	on	 healthcare	 systems	 in	 the	 coming	 years	 (Stevens	 et	 al.,	 2010).	 Renal	
disease	 is	 a	 risk	 factor	 for	 the	development	of	 CVD	 (Foley	 et	 al.,	 2005)	with	 some	 studies	
putting	 the	 risk	 of	 patients	 with	 chronic	 kidney	 disease	 (CKD)	 dying	 from	 cardiovascular	
complications	at	 twice	 that	of	non-CKD	patients	 (Collins	et	al.,	2003,	Go	et	al.,	2004).	This	
shows	that	in	the	future,	with	an	ageing	population,	renal	insufficiency	and	renal	disease	will	
need	to	be	addressed	as	a	cause	of	morbidity	and	mortality	in	the	UK	and	around	the	world.	




(Aydin	 et	 al.,	 2012)	 suggesting	 that	 the	 kidney	 is	 also	 susceptible	 to	 the	 DGal	 ‘model	 of	




on	the	 laboratory	mouse	outside	of	 the	CNS	to	 look	at	 it	 from	a	holistic	 standpoint.	Many	
factors	such	as	metabolic	ability	and	specifically	renal	function	were	to	be	measured	in	mice	
administered	 DGal	 versus	 naturally	 aged	 mice.	 The	 hope	 of	 this	 investigation	 was	 to	





DGal	was	 to	 be	 administered	 in	 the	drinking	water	 rather	 than	by	 intraperitoneal	 (i.p.)	 or	
subcutaneously	 (s.c.)	 injection.	 Due	 to	 the	 Home	 Office	 guidance	 and	 relating	 legislation	
under	 the	 animals	 (scientific	 procedures)	 act	 (ASPA)	 it	 is	 not	 possible	 to	 chronically	 inject	
DGal	 for	 6-8wk.	 This	 model	 had	 previously	 been	 proved	 to	 induce	 cognitive	 deficit	 and	







Ltd.	 (Margate,	Kent)	and	each	of	 the	below	described	procedures	were	carried	out	on	 the	
same	individuals	within	all	cohorts	unless	otherwise	specified.	Mice	were	received	into	the	
biological	 services	 unit	 at	 Takeda	 Cambridge	 Ltd.	 at	 9wk	 of	 age	 and	 housed	 under	 home	
office	regulations	until	sacrificed	at	3	(3mo),	12	(12mo)	or	24	(24mo)	months	of	age.	Mice	in	
DGal	 treated	groups	were	housed	 in	 the	 same	manner	as	3mo	mice	and	 received	DGal	 in	
their	drinking	water	at	doses	of	2g/kg/day	(low	dose),	4g/kg/day	(high	dose)	or	vehicle	(0.1%	





Mice	 were	 removed	 from	 cages,	 weighed,	 placed	 into	 retainers	 for	 a	 period	 of	
approximately	 5min	 while	 the	 MRI	 machine	 (EchoMRI™	 LLC,	 Houston,	 Texas,	 USA)	 was	
operational	 and	 then	 returned	 to	 cages	 following	 the	 completion	 of	measurements,	 with	












At	 numerous	 points	 throughout	 the	 study	 it	was	 necessary	 to	measure	 the	 blood	 glucose	
levels	 of	 the	mice.	 Blood	 glucose	measurement	was	 carried	 out	 by	 removing	 a	 very	 small	
1mm	section	of	the	end	of	the	tail	with	scissors	allowing	collection	of	a	small	drop	of	blood.	





for	 measurement	 of	 blood	 glucose,	 using	 a	 tail	 bleed.	 Approximately	 50μl	 of	 blood	 was	








blood	glucose	and	blood	 insulin	 (determined	 later	by	enzyme-linked	 immunosorbent	assay	
(ELISA))	 were	 measured,	 from	 tail-vein	 blood,	 before	 glucose	 was	 administered	 by	 oral	





were	weighed	 and	 a	 volume	of	 insulin	 for	 a	 dose	 of	 0.75U/kg	 established.	 Baseline	 blood	
glucose	 measurements	 were	 then	 made	 and	 the	 insulin	 administered	 i.p.	 Blood	 glucose	





CO2	 until	 dead;	 conformation	 of	 death	 was	 exsanguination	 by	 cardiac	 puncture.	 Blood	
collected	form	cardiac	puncture	was	then	spun	at	3000g	for	5min,	serum	was	collected	and	
stored	 at	 -80°C	 in	 aliquots	 for	 later	 analysis.	 Mice	 were	 fasted	 overnight	 (16h)	 prior	 to	


















Urine	 biomarker	 assays	were	 carried	 out	 on	 urine	 collected	 by	 housing	mice	 in	metabolic	
cages	 for	a	period	of	24h.	ELISAs	were	run	 for	albumin	 (Abcam.	Cambridge,	UK),	 lipocan-1	





All	 tissues	 were	 lysed	 in	 1%	 ice-cold	 dodecyl	 maltoside	 (DDM)	 lysis	 buffer	 using	
QIAshredder™	(Qiagen,	Hilden,	Germany)	tissue	homogeniser.	Tissues	were	weighed	and	1:5	
w/v	of	ice-cold	1%	DDM	buffer	added	before	homogenisation.	After	homogenisation,	lysates	




Cytokine	 levels	 in	 tissue	 and	 serum	were	 analysed	using	 commercially	 available,	multiplex	
(Mouse	 ProInflammatory	 7-Plex)	 assay	 kits	 from	 MesoScale	 Diagnostics	 (MSD)	 LLC.	

























cDNA	synthesis	 for	 analysis	by	quantitative	polymerase	 chain-reaction	 (q-PCR)	was	 carried	
out	 using	 QuantiTect®	 reverse	 transcription	 kit	 from	 Qiagen	 (Hilden,	 Germany)	 following	




cDNA	 samples	 synthesised	 from	 RNA	 samples	 from	 mouse	 organs	 were	 tested	 in	 q-PCR	
reactions.	These	reactions	were	set	up	 in	96-well	plates	using	TaqMan®	Fast	universal	PCR	












All	 values	 described	 are	 presented	 as	 mean	 ±	 standard	 error	 of	 the	 mean	 (SEM)	 for	 n	
replicates.	 Statistical	 validation	 and	 exclusion	 testing	 was	 performed	 using	 the	 statistics	














with	 the	most	 significant	difference	between	3	months	and	12	months	 (figure	2.1).	When	




Figure	 2.1.	 Lean	 vs.	 fat	 ratio	 for	 naturally-aged	 and	 3mo	 DGal	 treated	 mice.	 MRI	 data	 describing	
absolute	lean	and	fat	mass	processed	to	a	percentage	value	of	total	body	weight,	ratios	presented	for	
percentages	 of	 total	 body	 weight.	 3mo:	 n=12,	 12mo:	 n=12,	 24mo:	 n=14,	 vehicle:	 n=12,	 low	 dose:	













































was	 observed	 in	 ageing	 with	 no	 effect	 from	 DGal	 administration.	Mice	 in	 the	 24	months	





mice.	 A=Mass	 of	 food	 against	 time	 progression	 for	 24h.	 B=AUC	 analysis	 for	 A.	 3mo:	 n=12,	 12mo:	






























45,	 60	 and	 90	 min	 and	 against	 vehicle	 at	 45	 and	 60min.	 No	 difference	 was	 observed	
between	12	months	and	3	months	and	DGal	and	vehicle	throughout	the	test	(figure	2.5.A).	












No	 changes	 in	 serum	 total	 cholesterol	 (figure	 2.6.A)	 were	 observed	 between	 any	 groups.	
Serum	HDL	(figure	2.6.B)	showed	no	statistically	significant	differences	between	any	groups.	
Serum	 LDL	 (figure	 2.6.C)	 was	 significantly	 elevated	 in	 12	 months	 and	 24	 months	 groups	
versus	 3	 months.	 LDL	 was	 elevated	 in	 high	 dose	 DGal	 versus	 3	 months	 but	 not	 vehicle.	
















































































































































































becoming	 significant	 against	 3	 months	 at	 24	 months.	 The	 same	 increase	 is	 seen	 in	 all	
differentials	(figures	2.7.B,	C	&	D)	with	granulocytes	(figure	2.7.D)	also	significantly	increased	
at	12	months	versus	3	months	with	a	further	increase	to	24	months.	Total	WBC	count	(figure	






















No	 changes	 were	 observed	 between	 any	 groups	 in	 levels	 of	 either	 IFNγ	 (figure	 2.9.B)	 or	
TNFα	(figure	2.9.D).	IL-1β	(figure	2.9.A)	showed	an	increase	with	age	being	significant	against	










Following	the	protein	data	found	 in	the	kidney,	gene	expression	 levels	 for	cytokines	 in	the	





Figure	2.10.	2ΔΔCT	values	 for	expression	of	 IL-1β	 (A),	 TGFβ	 (B)	and	TNFα	 (C)	 for	naturally-aged	and	



























The	 only	 cytokine	 found	 to	 be	 detectable	 in	 the	 skeletal	 (Quadriceps)	 muscle	 was	 TNFα.	
TNFα	 shows	 an	 increasing	 trend	 with	 age,	 becoming	 significant	 at	 24	 months	 against	 3	
months.	 There	 was	 no	 significant	 difference	 observed	 between	 DGal	 treated	 and	 vehicle	
treated	animals	in	this	test.	
	


























































































































































































both	 12	 months	 and	 24	 months	 mice	 versus	 3	 months.	 DGal	 administration	 showed	 no	
significant	increase	in	normalised	creatinine	versus	vehicle	control.	
	
Figure	 2.15.	 Serum	 measurements	 of	 creatinine	 (A)	 and	 urea	 (B)	 as	 well	 as	 serum	 creatinine	
normalised	for	lean	mass	(C)	for	naturally-aged	and	3mo	DGal	treated	mice.	3mo:	n=12,	12mo:	n=12,	






Protein	 carbonylation	 (figure	 2.16.A)	 in	 12	 months	 animals	 was	 found	 to	 be	 significantly	
increased	 versus	 3	 months	 but	 no	 significance	 was	 found	 between	 any	 other	 groups.	


















































































to	 increase	 the	expression	of	 this	 enzyme,	with	 the	effect	more	profound	 in	DGal	 treated	


























3	 months	 at	 12	 months	 and	 continuing	 to	 be	 further	 significant	 against	 both	 12	 and	 3	
months	at	24	months.	 In	 figure	2.19.B	 there	 is	an	 increase	 in	Bowman’s	capsule	area	with	
age,	 becoming	 significant	 against	 3	 months	 at	 12	 months	 and	 continuing	 to	 be	 further	
significant	against	both	12	and	3	months	at	24	months.	Figure	2.19.C	presents	 the	area	of	
the	Bowman’s	capsule	as	a	percentage	of	 the	total	area	of	 the	renal	corpuscle,	 this	shows	
that	 there	 is	 an	 age-dependent	 increase	 in	 the	 area	 of	 the	 Bowman’s	 capsule	 becoming	
significant	 against	 3	 months	 at	 24	 months,	 this	 showed	 significance	 between	 12	 and	 24	
months.	
	
Figure	 2.19.	 Histological	 analysis	 of	 glomeruli	 from	 aged	 mice.	 A,	 glomerular	 area.	 B,	 Bowman’s	
capsule	area.	C,	%	of	 total	 area	occupied	by	Bowman’s	 capsule	B.	 ‘Biological	n’-	3mo:	n=12,	12mo:	
n=12,	24mo:	n=12.	‘Datapoint	n’	-	3mo:	n=240,	12mo:	n=240,	24mo:	n=240.	Data	presented	as	mean	






of	 Lopez-Otin	 et	 al.,	 (2013).	 These	 experiments	 are	 designed	 to	 make	 a	 comparison	 of	
natural	ageing	versus	administration	of	DGal.	We	used	increasing	age	and	low/high	dose	of	
DGal	to	create	two	‘dose-response	curves’	that	can	be	compared	to	one	and	other.	The	hope	
was	 to	 be	 able	 to	 use	 the	 ‘age	 dose-response	 curve’	 and	 ‘fit’	 the	 DGal	 dose	 to	 that	 for	
various	parameters,	showing	their	‘age’.	In	order	to	break	down	the	whole	picture	of	these	






storage	of	 fat	 combined	with	 failure	of	 insulin	 sensing	 shown	both	by	OGTT	and	 ITT	 tests	
means	that	these	experiments	suggest	animals	show	some	form	of	metabolic	syndrome	with	





When	 we	 look	 on	 to	 the	 lipid	 profile	 of	 these	 animals	 it	 is	 evident	 that	 there	 is	

















increases	 in	 inflammatory	markers	 like	 raised	WBC	 count	 and	 pro-inflammatory	 cytokines	
were	modest	and	as	a	rule	showed	an	increase	with	age	in	the	characteristic	‘age-response	
curve’	 which	 has	 been	 evident	 in	 many	 sets	 of	 results	 presented	 here.	 These	 results	 in	




markers	 we	 see	 in	 these	 animals,	 though	 the	 source	 is	 unclear	 from	 our	 investigations.	
Cellular	 death	 and	 damage	 which	 is	 linked	 to	 release	 of	 inflammation-causing	 Damage	
Associated	Molecular	Patterns	 (DAMPs)	 like	HMGB1	has	been	 suggested	as	a	promoter	of	
this	 inflammation	(Franceschi	et	al.,	2000).	 Induction	of	 inflammation	by	this	mechanism	is	





Another	 possible	 cause	 of	 this	 inflammation	 is	 mitochondrial	 dysfunction,	 which	 can	 be	
linked	to	the	induction	of	cellular	death	in	its	own	way	(Iyer	et	al.,	2013).	The	investigations	






an	 increase	 in	Nox-1	 and	 2	 expression	which	 follows	 the	 trend	 shown	 in	many	 cytokines.	
Interestingly,	 there	 is	 a	 dose-response	 increase	 in	 Nox-1	 with	 DGal	 treatment,	 Nox-1	 is	
known	 to	play	 a	 role	 in	 the	 induction	of	 inflammation	 (Singel	&	 Segal,	 2016,	 Zhang	et	 al.,	
2009)	but	there	is	no	increase	in	inflammatory	markers	seen	in	the	DGal	treated	groups.	It	is	
possible	that	this	is	evidence	that	oxidative	stress,	here	shown	as	Nox	enzyme	expression,	is	







so	 it	 could	 also	 be	 suggested	 that	 inflammation	may	be	 as	 a	 result	 of	 increased	oxidative	
















Figure	 2.20.	 AGE	 in	 differing	 areas	 of	 the	 brain	with	 DGal	 treatment	 (from	 Chadwick	 et	 al.,	 under	
review).	
	
The	 other	 aspect	 of	 inflammation	 here	 is	 the	 question	 of	 the	 source	 of	 inflammation.	
Although	 these	 investigations	were	 focused	on	 the	kidney	 it	was	 important	 to	explore	 the	
effect	of	holistic	 inflammation	on	 the	whole	body.	 Initial	 indications	 in	 the	kidney	 showed	






for	 the	 differing	 distribution	 of	 KC	 is	 unclear,	 it	 could	 be	 suggested	 that	 it	 is	 due	 to	 high	
	 88	
blood	 flow	 as	 both	 kidneys	 and	 lungs	 appear	 to	 have	 high	 protein	 levels,	 as	 does	 the	
circulation.	The	lack	of	KC	presence	in	the	liver	which	also	has	a	very	high	blood	flow	would	
suggest	that	circulatory	effects	are	not	a	major	driver	of	this	tissue	distribution.	Ultimately,	




The	 investigations	 in	 this	chapter	were	ultimately	aimed	at	assessing	the	ability	of	DGal	 to	
induce	renal	ageing	for	research	modelling	purposes.	The	major	factor	which	is	important	to	
model	 when	 looking	 at	 renal	 ageing	 is	 any	 change	 in	 renal	 function.	 Changes	 in	 renal	
function	are	well	known	to	be	linked	with	ageing	(O’Hare	et	al.,	2007,	Davies	&	Shock	1949)	







commonly	 elevated	 in	 renal	 injury	 indicating	 poor	 healthcare	 outcomes	 (Parfrey	 et	 al.,	
1996).	 Serum	 creatinine	 in	 aged	 and	 DGal	 animals	 was	 found	 to	 be	 elevated	 when	
normalised	for	muscle	wastage,	which	was	important	in	this	study,	given	the	very	different	
lean	masses	of	young	and	old	animals	(Cockcroft	&	Gault,	1976).		There	is	some	sort	of	renal	
impairment	 in	 these	 animals;	 this	 may	 be	 associated	 with	 a	 hyperfiltration	 seen	 in	 early	
stage	 renal	 failure	 (Palatini,	 2012)	 and	 can	 be	 a	 risk	 factor	 for	 the	 development	 of	more	












Urinary	 markers	 of	 renal	 injury	 in	 this	 study	 showed	 no	 significance	 in	 any	 parameter,	
however	some	trends	were	evident.	The	key	urinary	marker	of	glomerular	function,	ACR	was	
unchanged	with	age,	likely	to	mean	that	if	there	is	renal	injury	that	it	 is	sub-clinical.	ACR	in	
DGal	 treated	mice	was	 increased	 versus	 vehicle	 control,	 though	 this	may	 have	 been	 as	 a	
result	of	a	very	high	creatinine	within	this	group	and	none	of	these	findings	were	statistically	
significant.	N-Gal	 is	 a	marker	 of	 renal	 inflammation	 and	damage	 (Mishra	 J	 et	 al.,	 2005);	 it	













Ultimately,	 these	 investigations	 have	 concluded	 that	 the	 DGal	 model	 is	 not	 suitable	 for	
modelling	of	whole-body	ageing.	The	lack	of	inflammation,	which	is	either	a	marker	or	driver	
of	 ageing,	 in	 the	 kidney	or	 indeed	 any	 other	 organs	with	DGal	 treatment	means	 that	 it	 is	
hard	 to	believe	DGal	has	any	effect	on	 the	body	outside	of	 the	CNS.	 For	 this	model	 to	be	
used	 for	 renal	 ageing	 studies	 specifically	 it	 is	 important	 that	 if	 there	 is	 any	 renal	 injury	
induced,	 that	 it	 be	 mimetic	 to	 that	 induced	 by	 ageing.	 The	 renal	 injury	 seen	 with	 DGal	
treatment	seems	to	not	be	similar	enough	to	that	of	ageing	and	is	in	fact	a	pathology	in	its	
own	right.	Animal	models	of	disease	are	never	perfect	as	it	is	almost	impossible	to	recreate	
an	 exact	 pathology	 artificially	 in	 an	 animal	 so	 it	 is	 important	 that	 we	 use	 models	
appropriately	and	understand	their	shortcomings.	It	seems	that	the	DGal	model	does	induce	
















drug	 has	 since	 been	 approved	 by	 the	 food	 and	 drug	 administration	 (FDA)	 and	 European	
medicine	agency	(EMA)	for	use	in	clinic	for	RA;	however,	it	has	been	suggested	that	it	could	
have	 beneficial	 effects	 in	DN.	 This	 suggestion	was	 as	 a	 result	 of	 earlier	 studies	 showing	 a	
marked	activation	of	the	Jak/STAT	pathway	 in	patients	with	DN	(Brosius,	Tuttle	&	Kretzler,	
2016).	Indeed,	our	own	results	(Chapter	IV)	show	that	there	is	a	sharp	increase	in	expression	
of	 the	 Jak/STAT	 machinery	 and	 evidence	 of	 activation	 in	 a	 number	 of	 pro-inflammatory	
states	within	the	kidney.	
	
In	 RA	 Jak/STAT	 inhibitors	 lower	 activation	of	 the	 cell	 (Goldstein	 et	 al.,	 2016)	 and	humeral	
(Wang	et	al.,	2014)	mediated	immune	systems	by	blocking	signal	transduction	of	cytokines.	
Importantly	 certain	 cytokines	 are	 key	 in	 its	 activation	 IL-6	 (Heinrich	 et	 al.,	 2003),	 IL-2	
(Goldstein	et	al.,	2016)	and	 IL-4	 (Wang	et	al.,	2014)	among	others.	This	 leads	 to	 the	 initial	
thought	 that	 this	 drug	 may	 act	 to	 prevent	 their	 downstream	 action	 and	 even	 upstream	
cytokine	 production,	 in	 short,	 a	 strong	 generalised	 anti-inflammatory	 (Brosius,	 Tuttle	 &	
Kretzler,	2016).	
	




have	 been	 implicated	 heavily,	 along	 with	 mesangial	 cells	 (Mauer	 et	 al.,	 1984)	 in	 the	
pathogenesis	 of	 DN	 (Susztak	 et	 al.,	 2006).	 Mesangial	 expansion	 results	 in	 the	 ultimate	
occlusion	of	 the	afferent	blood	vessels	and	 in	 ischaemia	of	 the	glomerulus	 (Abrass,	1995).	








alternative	 pathway	 other	 than	 simply	 the	 transduction	 of	 cytokine	 signals	 to	 activate	
immune	 cells.	 Jak/STAT	 signaling	 is	 heavily	 involved	 with	 cell	 survival	 and	 proliferative	
pathways	 as	 it	 signals	 for	 a	 number	 of	 growth	 factors	 and	 cytokines,	 like	 TGFβ	 and	 TNFα	
which	 can	modulate	 cell	 cycle	 progression	 (Lovibond	 et	 al.,	 2003).	 It	 has	 specifically	 been	
suggested	 that	 the	 Jak/STAT	 pathway	 is	 involved	 in	 the	 pathogenesis	 of	 diabetic	
glomerulopathy	and	mesangial	expansion	(Berthier	et	al.,	2009).	
	
Downstream	of	 Jak	and	STAT	activation	 is	 the	upregulation	of	 the	 suppressors	of	 cytokine	
signalling	(SOCS).	SOCS	role	is,	as	the	name	might	suggest,	to	act	as	a	negative	feedback	on	
cytokine	 signalling	 initiated	 by	 Jak/STAT	 activation	 (Yoshimura,	 Naka	 &	 Kubo,	 2007).	 The	
mechanism	 of	 this	 is	 shown	 in	 figure	 3.1	 where	 by	 binding	 of	 a	 cytokine	 to	 its	 receptor	




and	 induced	 in	 the	 same	manner,	 this	 protein	 sterically	 blocks	 the	binding	of	 STAT	 to	 the	
cytokine	receptor,	preventing	its	activation.	
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Figure	 3.1.	 A,	 induction	 of	 SOCS	 expression	 by	 binding	 of	 cytokine	 to	 its	 receptor	 activating	 the	
Jak/STAT	pathway.	B,	SOCS	proteins	targeting	phosphorylated	Jak	to	inhibit	and	degrade	them	as	well	




DM	 (Rønn,	 Billestrup	 &	 Mandrup-Poulsen,	 2007).	 Both	 its	 action	 in	 reducing	 insulin	
resistance	 (Rui	 et	 al.,	 2002)	 and	 its	 role	 in	 glomerulopathy	 (Zhou	 et	 al.,	 2014)	 has	 been	
explored.	 SOCS	 are	 essentially	 Jak/STAT	 blockers	 that	 occur	 as	 a	 natural	 part	 of	 the	 cells	
machinery,	 making	 them	 similar	 to	 Jakinibs	 in	 that	 they	 abrogate	 signalling	 through	 this	
mechanism	and	therefore	alter	 the	cellular	changes	 Jak/STAT	activation	 invokes.	 Indeed,	 it	





this	 drug	 reduces	 urinary	 ACR.	 The	 results	 of	 this	 study	 are	 shown	 below	 in	 figure	 3.2,	
showing	 that	 there	 is	 a	 dose	 dependent	 reduction	 in	 the	 ACR	 of	 patients	 treated	 with	
baricitinib.	The	results	of	this	study	 indicate	that	there	is	efficacy	 in	the	use	of	this	class	of	
drugs	in	patients	with	DN	but	no	mechanism	of	action	is	discussed.	The	authors	to	this	study	










on	 the	 kidney.	When	we	 think	 about	 animal	models	 of	DM	 that	 are	most	 appropriate	 for	
testing	 this	 drug	 pre-clinically	 it	 is	 important	 to	 remember	 the	 mode	 of	 induction.	 Most	
animal	models	of	diabetes	currently	use	a	genetic	or	T1DM-like	 induced	mode	of	action	to	
adjust	 insulin	 signalling	 rather	 than	 the	 insulin	 resistance	 brought	 on	 by	 T2DM.	 It	 would	
seem	 prudent	 to	 explore	 the	 mechanism	 of	 action	 of	 these	 drugs	 in	 T2DM	 to	 better	







begin	 understanding	 the	 mechanism	 of	 action	 of	 Jakinibs	 in	 ameliorating	 renal	 injury	 in	











1. Chow:	 Housed	with	 access	 normal	mouse	 chow	 diet	 from	 LabDiet	 (St.	 Louis,	MO)	
and	water	ad	libitum	for	14wk.	
2. Vehicle:	 	 Housed	 with	 access	 to	 high-fat	 diet	 (HFD)	 (AIN-76A	 w/58%	 fat	
energy/sucrose/red)	 from	TestDiet	 (St.	 Louis,	MO)	 and	water	ad	 libitum	 for	 14wk.	
After	 6wk	 on	 experimental	 diet,	 these	 mice	 were	 administered	 4%	 dimethyl	
sulphoxide	(DMSO)	vehicle	p.o.	by	oral	gavage	daily	for	the	remainder	of	the	study.	
3. Baricitinib:	 Housed	 with	 access	 to	 HFD	 (AIN-76A	 w/58%	 fat	 energy/sucrose/red)	





once	a	week	 to	monitor	health	 and	appetite.	At	 completion	of	 the	 study	 after	 14wk	 total	
mice	 were	 sacrificed	 by	 overdose	 of	 ketamine/xylazine	 and	 exsanguinated	 by	 cardiac	
puncture	before	organs	were	collected	 for	analysis.	Blood	collected	 form	cardiac	puncture	
was	 then	 spun	 at	 3000g,	 serum	 was	 collected	 and	 stored	 at	 -80°C	 in	 aliquots	 for	 later	








was	measured	 at	 T=10min,	 30min,	 45min,	 60min	 and	90min.	Blood	 glucose	measurement	






were	weighed	 and	 a	 volume	of	 insulin	 for	 a	 dose	 of	 0.75U/kg	 established.	 Baseline	 blood	





was	 carried	 out	 under	 sterile	 conditions	 and	 temperature	 was	 maintained	 at	 37°C	
throughout.	 Mice	 were	 anaesthetised	 using	 isoflurane,	 abdominal	 hair	 removed	 and	
injected	with	0.3mg/kg	buprenorphine	s.c.	A	full	midline	laparotomy	was	performed	and	the	
kidneys	 exposed.	 Renal	 pedicles	 were	 isolated	 and	 clamped	 using	 non-traumatic	
microvascular	 clamps	 for	30min.	Following	 reperfusion	 the	cavity	was	closed	using	proline	
suture	and	administered	0.5ml	saline	i.p.	Mice	were	recovered	and	returned	to	their	cages	
















Tissue	 for	 analysis	 was	 lysed	 using	 ice-cold	 radioimmunoprecipitation	 assay	 (RIPA)	 buffer	
with	protease	and	phosphatase	inhibitors	in	a	bead	lyser.	Tissues	were	lysed	with	a	3:1	w/v	















pathology	 scanner	 (Hamamatsu	Photonics	 K.K.,	 Japan).	Glomerular	 and	Bowman’s	 capsule	
sizes	 were	 assessed	 using	 the	 Nanozoomer	 NDP	 viewer	 software	 (Hamamatsu	 Photonics	
K.K.,	 Japan).	Two	cross-sectional	measurements	 (at	90°	 to	one	another)	were	 taken	 for	20	
renal	 corpuscles	 and	 averaged	before	 an	 area	 for	 each	was	 established	using	 the	 formula	
A=πr2	with	20	representative	glomeruli	being	used	per	mouse.		
Periodic	Acid	Schiff	staining	was	also	performed	on	different	sections	of	the	same	samples.	















cDNA	 samples	 synthesised	 from	 RNA	 samples	 from	 mouse	 organs	 were	 tested	 in	 q-PCR	
reactions.	These	reactions	were	set	up	 in	96-well	plates	using	TaqMan®	Fast	universal	PCR	
master	 mix	 (ThermoFisher,	 MA,	 USA).	 Probes	 were	 VIC-labelled,	 MGB-quenched	 GAPDH	
probe	 for	 control	 housekeeping	 gene	 and	 FAM-labelled,	 MGB-quenched	 gene	 of	 interest	
probes.	Protocol	was	run	using	One	Step	Plus	q-PCR	machine	from	Applied	Biosystems	and	






Immortalised	 human	 podocyte	 cells	 were	 obtained	 from	 the	 laboratory	 of	 Prof.	 Moin	
Saleem	of	the	University	of	Bristol.	These	cells	were	cultured	in	RPMI	medium	(Thermo,	UK)	
with	 10%	 Fetal	 Bovine	 Serum	 (FBS)	 (ThermoFisher,	 MA,	 USA),	 5%	 penicillin/streptomycin	
(pen/strep)	 (ThermoFisher,	 MA,	 USA)	 and	 5%	 Insulin,	 Transferrin	 and	 Selenium	 (ITS)	
(ThermoFisher,	 MA,	 USA).	 Cells	 were	 grown	 to	 80-90%	 confluence	 at	 32°C	 and	 then	
transferred	 to	an	 incubator	at	37°C	 for	 a	period	of	2wk	 to	differentiate.	 These	 cells	had	a	
heat	 activated	 ‘T-antigen’	 allowing	 them	 to	 grow	 undifferentiated	 at	 32°C	 before	 being	
differentiated	at	37°C	at	which	point	the	cease	to	multiply	any	further	and	express	podocyte	
specific	 markers.	 All	 cells	 were	 used	 for	 experiments	 within	 3	 days	 of	 reaching	 full	
differentiation.	 Cells	 had	 a	 medium	 change	 2h	 before	 human	 recombinant	 (hr)IL-6	 was	
‘spiked	in’	to	a	concentration	of	100nM	with	baricitinib	in	0.1%	DMSO	vehicle	and	incubated	
for	 6h.	 Cells	 were	 lysed	 for	 protein	 analysis	 using	 ice-cold	 RIPA	 buffer	 with	 protease	 and	
phosphatase	 inhibitors.	After	homogenisation,	 lysates	were	 centrifuged	at	 3000g	 for	 5min	





measured	 using	 a	 standard	 BCA	 assay	 (ThermoFisher,	 MA,	 USA)	 and	 diluted	 to	 a	
concentration	of	1mg/ml	 total	protein.	Samples	were	denatured	and	 reduced	with	 lithium	
dodecyl	 sulphate	 (LDS)	 loading	 buffer	 (ThermoFisher,	 MA,	 USA)	 plus	 reducing	 agent	
(ThermoFisher,	MA,	USA)	at	70°C	 for	10min.	10μg	of	protein	was	added	 to	each	well	of	 a	
sodium	 dodecyl	 sulphate-polyacrylamide	 gel	 electrophoresis	 4-12%	 Bis-Tris	 gel	
(ThermoFisher,	MA,	 USA)	 and	 run	 until	 the	 protein	 front	 reached	 the	 bottom	 of	 the	 gel.	
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Proteins	 were	 transferred	 to	 nitrocellulose	 membranes	 using	 an	 iBlot	 system	 from	
(ThermoFisher,	 MA,	 USA).	 Membranes	 were	 then	 probed	 using	 antibodies	 from	 cell	
signalling	technologies	(CST)	(Danvers,	MA,	USA)	with	phospho/total	parings	from	different	
host	 animals.	 Fluorescent	 secondary	 antibodies	 from	 LiCor	 (Lincoln,	 NE,	 USA)	 were	 used,	
with	 different	 wavelengths	 for	 phospho/total	 proteins	 when	 needed,	 these	 membranes	













(RM)	 ANOVA	 with	 Bonferroni’s	 post-hoc	 test	 using	 using	 GraphPad™	 Prism®	 6	 for	 mac	











































No	 significance	 was	 found	 between	 the	 serum	 creatinine	 of	 any	 groups	 in	 figure	 3.6.A.	
Figure	3.6.B	shows	a	small	but	significant	decrease	in	serum	urea	in	baricitinib	mice	versus	
chow	with	no	significance	between	chow	and	vehicle	or	vehicle	and	baricitinib.	Urinary	ACR	
(figure	3.6.C)	 is	 significantly	 elevated	 in	 vehicle	 and	baricitinib	mice	against	 chow.	Mice	 in	














Representative	 images	of	 the	 renal	 corpuscles	 analysed	 are	 shown	 in	 figure	 3.7.	 It	 can	be	
seen	 in	 figure	 3.7	 that	 there	 is	 an	 increase	 in	 glomerular	 area	 and	 expansion	 of	 the	
Bowman’s	capsule	in	the	vehicle	group	(figure	3.7.B)	when	compared	to	chow	mice	(figure	
3.7.A),	 this	 increase	 in	 these	 parameters	 is	 not	 seen	 in	 baricitinib	 treated	 animals	 (figure	
3.7.C).	 	 Analysis	 of	 the	 area	 of	 the	 glomerulus	 (figure	 3.8.A)	 showed	 that	 there	 was	 a	
significant	increase	in	area	in	vehicle	treated	mice	versus	both	chow	and	baricitinib	with	no	
significance	 between	 chow	 and	 baricitinib.	 Bowman’s	 capsule	 area	 (figure	 3.8.B)	 showed	
that	there	was	a	significant	increase	in	the	area	in	vehicle	mice	versus	chow	and	baricitinib	
with	 no	 difference	 between	 chow	 and	 baricitinib.	 When	 the	 area	 of	 the	 glomerulus	 was	
established	as	a	percentage	of	total	corpuscle	area	(figure	3.8.C)	it	was	found	that	this	was	
significantly	 decreased	 in	 vehicle	 treated	 mice	 versus	 both	 chow	 and	 baricitinib	 with	 no	
difference	between	chow	and	baricitinib.	









to	 bowman’s	 capsule	 area.	★	P≤0.05	 vs.	 Chow	 when	 analysed	 by	 one-way	 ANOVA.	 ‘Biological	 n’:	
















Renal	 expression	 of	 Mafb	 (figure	 3.10.A)	 was	 significantly	 elevated	 in	 the	 vehicle	 group	
against	chow	and	baricitinib	with	no	significance	between	chow	and	baricitinib.	Expression	














mice	 against	 both	 chow	 and	 baricitinib	 with	 no	 difference	 between	 chow	 and	 baricitinib	
groups.	 IL-10	 (figure	 3.11.C)	 was	 significantly	 decreased	 in	 vehicle	 and	 baricitinib	 against	
chow	with	no	significance	between	vehicle	and	baricitinib.	
	
Figure	3.11.	 Pro-Inflammatory	 cytokines	 levels	 from	normalised	 kidney	 lysate	 for	mice	 fed	 chow	or	







no	 significance	 between	 any	 groups	 though	 it	 was	 found	 to	 be	 higher	 in	 vehicle	 treated	
animals	 with	 no	 clear	 difference	 between	 chow	 and	 baricitinib.	 p21cip1/waf1	 (figure	 3.12.C)	
was	significantly	elevated	 in	animals	 treated	with	vehicle	versus	both	chow	and	baricitinib	



















Baricitinib	 and	 vehicle	 treated	 animals	 had	 significantly	 higher	 urea	 (figure	 3.14.A)	 and	
creatinine	 (figure	 3.14.B)	 versus	 sham	 animals.	 Baricitinib	 and	 vehicle	 groups	 showed	 no	
significance	between	each	other	for	both	creatinine	and	urea.	
	

























it	 is	 a	 generalised	 anti-inflammatory	 or	 works	 by	 some	 other	 mechanism	 is	 yet	 to	 be	
answered.	 It	 seems	 logical	 that	a	pathway	 involved	 in	 the	 transduction	of	 cytokine	 signals	
could	be	considered	 inflammatory,	especially	when	 these	signals	 induce	processes	such	as	
lymphopoiesis	and	T-cell	activation	but	the	ubiquitous	expression	of	the	mechanism	means	
that	effects	 could	be	 far	more	wide	 ranging	 than	 simply	 immune	activation.	 The	 Jak/STAT	
pathway	and	its	activation	have	long	been	seen	as	a	key	part	of	the	link	between	cancer	and	
inflammation	(Yu,	Pardoll	&	Jove,	2009).	They	have	an	important	role	to	play	in	the	control	
cell	 cycle	 signals	 from	 growth	 factors	 and	 in	 response	 to	 cytokine	 signals	 (Bhunia	 et	 al.,	
2002).	 In	 addition	 to	 this	 it	 is	 important	 to	 bear	 in	mind	 that	 the	 Jak/STAT	 pathway	 also	





animals	 is	 significantly	 reduced	 against	 vehicle	 controls.	 Serum	 renal	 markers	 are	 also	
reduced	 in	drug	 treated	animals	but	 it	 is	not	 raised	 in	animals	 treated	with	vehicle	 so	 this	








and	 ITT	 showed	 that	 there	 was	 a	 significant	 inhibition	 of	 insulin	 sensitivity	 with	 high-fat	
feeding	compared	to	chow.	Interestingly	baricitinib	administration	did	not	change	the	insulin	
sensitivity	of	these	animals,	this	goes	against	the	findings	of	Khan	et	al.,	 (2015)	who	found	
that	 insulin	 sensitivity	 was	 improved	 with	 baricitinib	 in	 HFD	 animals.	 However,	 in	 our	
experiments	 this	 lends	 credence	 to	 the	 argument	 that	 this	 drug’s	 efficacy	 is	 not	 due	 to	 a	
disease	modification	but	a	more	specific	mechanism.	Animals	fed	with	HFD	and	treated	with	
vehicle	 had	 an	 increase	 in	 random	 blood	 glucose,	 perhaps	 analogous	 with	 a	 reading	 in	





Histological	 analysis	 of	 the	 terminal	 nephron	 from	mice	 in	 this	 study	 shows	 the	 classical	
histological	 changes	 associated	 with	 DN	 in	 animals	 fed	 with	 HFD	 (Pourghasem,	 Shafi	 &	
Babazadeh,	2015).	Animals	on	HFD	showed	an	increasing	size	of	glomerulus	compared	with	
chow	 animals	 and	 an	 expansion	 of	 the	 Bowman’s	 capsule	 relative	 to	 the	 glomerulus,	
indicative	 of	 a	 change	 in	 osmotic	 potential	 and	 filtration	 rate	 of	 the	 glomerulus	
(Tomlanovich	et	al.,	1987).	Expansion	 in	 the	size	of	 the	Bowman’s	 space	 in	 the	kidney	has	
been	 linked	 to	 changes	 in	 glomerular	 colloid	 (or	 oncotic)	 pressure	 due	 to	 the	 leakage	 of	
albumin	into	the	filtrate	changing	the	osmotic	potential	of	the	filtrate	comparatively	to	the	
blood	in	the	capillaries	(Pollak	et	al.,	2014).	Baricitinib	seems	to	prevent	the	dilation	of	the	





proteinuria.	 It	 appears	 from	 these	 histological	 findings	 that	 there	 is	 less	 expansion	 of	 the	
glomerulus	 in	animals	 treated	with	baricitinib,	 leading	us	 to	believe	 that	 this	 is	a	potential	





expression	of	SOCS	as	 these	are	downstream	of	 Jak/STAT	activation	 (Aaronson	&	Horvath,	
2002).	 It	has	previously	been	shown	that	 increases	 in	SOCS	expression	are	beneficial	 in	DN	
(Zhou	et	al.,	2014).	Our	study	shows	that	there	is	an	upregulation	of	this	in	DN	and	that	this	
is	completely	 reversed,	 the	beneficial	effects	of	SOCS	over	expression	may	well	have	been	
due	 to	 the	 suppressive	 effect	 these	 have	 on	 the	 Jak/STAT	 pathway.	 In	 our	 study,	 SOCS	




is	 elevated	 under	 the	 diseased	 state	 compared	 with	 sham	 and	 reduced	 with	 addition	 of	
baricitinib.	This	could	indicate	something	that	has	not	yet	been	suggested	in	the	literature,	




Jak/STAT	activation	and	 its	high	 level	of	expression	 is	 resulting	 in	differential	changes	and,	




that	baricitinib	has	 in	DN,	 cytokines	 tell	 an	 interesting	and	 conflicting	 story.	 The	 canonical	
DM	 cytokines,	 IL-1β	 and	 TNFα	 (Salminen,	 Kaarniranta	 &	 Kauppinen,	 2012)	 would	 be	
expected	 to	 all	 be	 significantly	 elevated.	 It	 is	 therefore	 counterintuitive	 that	 IL-1β	 is	 not	
significantly	increased	in	the	kidneys	of	mice	fed	with	HFD.	It	is	also	to	be	noted	that	KC,	not	
always	 associated	 with	 DN	 but	 has	 been	 implicated	 (Tashiro	 et	 al.,	 2002)	 and	 is	 often	
associated	 with	 acute	 renal	 inflammation	 (Harada	 et	 al.,	 1994).	 The	 early	 phase	 of	 DN	 is	
where	KC	is	most	expected	(Tashiro	et	al.,	2002)	and	this	is	the	stage	which	we	intended	on	
modelling	 in	 these	 animals,	 so	 this	 finding	 does	 not	 support	 the	 conclusion	 that	 these	
animals	are	in	early	stage	DN.	IL-10	was	found	to	be	depressed	in	animals	fed	with	HFD,	this	
does	 paint	 a	 picture	 of	 a	 pro-inflammatory	 environment	 given	 the	 anti-inflammatory	
properties	 of	 IL-10	 (Iyer	 &	 Cheng,	 2012).	 The	 only	 cytokine	 that	 was	 affected	 by	
administration	of	baricitinib	was	TNFα,	 this	 is	 an	 interesting	 finding	 in	 that	TNFα	 is	 chiefly	
produced	by	activated	macrophages.	Macrophages	 can	be	activated	 through	 the	 Jak/STAT	
signalling	pathway	with	cytokines	like	IL-4	and	IL-13	(Gordon,	2003)	so	it	could	well	be	that	
the	 increase	 in	 macrophage	 activation	 came	 from	 IL-13	 (no	 data	 available)	 which	 was	
suppressed	 by	 inhibition	 of	 the	 Jak/STAT	 pathway.	 It	 is	 also	 interesting	 that	 IL-2,	 highly	
important	 in	 T-cell	 activation	 (Suzuki	 et	 al.,	 1995),	 is	 not	 changed	 in	 anyway	 during	 HFD	
feeding	and	Jak/STAT	inhibition.	T-cells	to	this	point	have	not	been	shown	to	have	a	strong	
association	with	 the	pathology	of	DN	so	 it	 is	perhaps	unsurprising	 that	 this	cytokine	 is	not	





and	 certainly	 not	what	 analysis	 of	 human	 samples	 has	 shown	 (Navarro-González	&	Mora-
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Fernández,	 2008).	 It	 could	 be	 claimed	 that	 this	 model	 is	 only	 of	 an	 early	 stage	 of	 DN	 or	
perhaps	 that	our	model	does	not	 fully	model	 the	human	disease	state.	When	we	consider	
the	 impact	 of	 baricitinib	 on	 inflammation	 in	 this	 model	 it	 seems	 that	 there	 is	 little	








ischaemia	 reperfusion	 injury	 in	our	model	of	AKI.	As	 a	model	of	 acute	 renal	 inflammation	
this	 induces	 renal	 inflammation	 and	 fibrosis	 and	 results	 in	 the	 acute	 elevation	 of	 serum	
creatinine.	Given	 the	efficacy	 shown	by	baricitinib	 in	RA,	 a	disease	of	 chronic,	 rather	 than	
acute	 inflammation	 it	 then	seems	sensible	to	explore	the	potential	of	baricitinib	 in	a	more	
chronic	model	 of	 renal	 injury.	 Data	 produced	 within	 our	 laboratory	 by	 an	 undergraduate	
placement	student,	Vicky	Merezhko,	under	the	guidance	of	myself	and	other	PhD	students	is	
shown	in	figure	3.15.	This	data	indicates	that	when	baricitinib	is	used	in	the	model	of	renal	
fibrosis,	 UUO,	 it	 does	 not	 reduce	 the	 injury	 resulting	 from	 this	 model	 (Merezhko	 et	 al.,	
2016).	This	 is	not	truly	a	model	of	renal	 inflammation	but	of	fibrosis,	so	the	most	common	
measure	 of	 injury	 is	 to	 quantify	 collagen	 and	 fibrin	 deposits	 by	 Picro-Sirius	 Red	 (PSR).	
Collagen	and	fibrin	deposits	are	an	indicator	of	fibroblast	and	macrophage	activation,	which	
would	be	expected	to	be	reduced	 if	 there	was	a	 reduction	of	 renal	 inflammation,	which	 is	
not	 seen	 when	 treated	 with	 baricitinib.	 These	 findings	 in	 other	 models	 of	 renal	









Downstream	 of	 Jak/STAT	 activation	 are	 many	 parts	 of	 the	 machinery	 for	 cell	 cycle	
modulation.	p21cip1/waf1	 for	example	plays	a	pivotal	role	 in	cell	cycle	arrest	and	induction	of	
apoptosis	via	the	Jak/STAT	pathway	(Bhunia	et	al.,	2002).	We	see	that	p21cip1/waf1	is	present	





kidneys	 of	 mice	 subjected	 to	 experimental	 diabetic	 nephropathy	 (Kuan,	 Al-Douahji	&	
Shankland,	 1998).	 When	 we	 consider	 a	 driver	 for	 mesangial	 expansion	 in	 these	
experiements	 then	 p21cip1/waf1	 would	 be	 a	 clear	 choice	 for	 this,	 given	 its	 highly	 significant	
elevation	 in	 p21cip1/waf1	 in	 the	 kidneys	 of	 animals	 that	 have	 shown	 significant	 mesangial	
expansion.	
	
When	we	consider	 the	effects	of	baricitinib	 in	 these	experiments	 it	 is	 clear	 that	 it	 reduces	
the	expression	of	p21cip1/waf1	in	the	kidneys	of	these	animals	and	considering	the	role	which	
p21cip1/waf1	 has	 been	 shown	 to	 play	 in	 inducing	mesangial	 expansion,	 this	 is	 a	 highly	 likely	
mechanism	of	action.	 It	has	been	shown	that	p21cip1/waf1	 inhibition	results	 in	a	reduction	 in	
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the	 mesangial	 matrix	 over-secretion	 associated	 with	 atherosclerosis	 (Weiss	 &	 Randour,	
2002),	it	therefore	becomes	logical	following	the	work	of	Bhunia	et	al.	(2002)	that	inhibition	






To	 conclude,	 the	 results	 seen	by	Tuttle	et	 al.,	 2015	appear	 to	be	 reproducible	 in	 a	mouse	
model	of	DN	induced	by	feeding	with	HFD	under	our	conditions.	This	‘back-translation’	from	
human	 studies	 into	 mice	 has	 enabled	 us	 to	 make	 some	 interesting	 in-roads	 towards	
discovering	 the	 specific	mechanism	 by	which	 baricitinib	makes	 its	 positive	 effects	 on	 this	
disease	state.	Baricitinib	appears	to	have	very	little	effect	on	the	inflammatory	status	of	the	
diabetic	kidney	but	does	appear	to	have	an	 impact	on	the	cell	cycle	of	the	cells	within	the	
kidney.	 Given	 the	 prominent	 role	 of	 the	 glomerular	 apparatus	 in	 DN	 and	 the	 lack	 of	















with	 both	 obesity	 and	 DM.	 This	 condition	 is	 dangerous	 for	 patients	 with	 DM	 as	 it	 is	 a	
contributory	factor	in	the	elevated	risk	of	CVD	in	the	population	(Haffner	et	al.,	1998)	as	well	
as	leading	to	worsening	of	the	diabetic	condition	itself	(Lupi	et	al.,	2002,	Khan	et	al.,	2015).	
Treatment	 for	 these	 is	 normally	 associated	 with	 conventional	 cholesterol-lowering	
medication,	 such	 as	 statins	 (NICE,	 2016).	 Drug	 treatments	 targeted	 at	 the	 underlying	






the	 part	 that	 must	 play	 in	 developing	 diabetes	 (Khan	 et	 al.,	 2015).	 It	 has	 further	 been	
suggested	that	amelioration	of	inflammation	in	adipose	tissues	can	lead	to	a	reduction	in	an	
elevated	lipid	(specifically	cholesterol)	profile	of	mice	fed	with	a	HFD	(Neyrinck	et	al.,	2013).	
Moreover,	 it	 is	 shown	 by	 Khan	 et.al	 (2015)	 that	 there	 is	 a	 role	 of	 Jak/STAT	 related	






many	 changes	 in	 physiology.	 As	 a	 method	 of	 energy	 transfer	 within	 the	 body,	 fats	 and	
specifically	 free	 fatty	 acids	 (FFA),	 their	 synthesis,	 degradation,	 storage	 and	 usage	 are	
controlled	by	the	hormones	insulin	and	glucagon.	Though	insulin	and	glucagon	are	the	major	
metabolic	 hormones	 within	 the	 body,	 their	 release	 is	 heavily	 influenced	 by	 signals	 from	
outside.	 The	 part	 that	 glucose	 has	 to	 play	 in	 the	 release	 of	 insulin	 and	 glucagon	 is	 well	
known	and	has	been	covered	 in	chapter	 I.	More	applicable	 to	 this	 chapter	however	 is	 the	






















Glucagon-like	 peptide-1	 is	 released	 from	 intestinal	 L-cells	 in	 response	 to	 glucose	 and	 fat	
intake	 to	 the	 stomach	and	 is	produced	 from	alternate	 splicing	of	 the	proglucagon	gene	as	
shown	 in	 figure	4.2.	Figure	4.2	shows	that	there	 is	an	alternate	splicing	of	 this	gene	 in	the	











Figure	 4.2.	 Structures	 of	 (A)	 the	 proglucagon	 gene,	 (B)	 mRNA,	 and	 (C)	 protein.	 (D)	 Tissue-specific	
posttranslational	 processing	 of	 proglucagon	 in	 the	 pancreas	 leads	 to	 the	 generation	 of	 Glicentin-
related	 polypeptide	 (grpp),	 glucagon	 (gluc),	 intervening	 peptide-1	 (ip-1),	 and	 major	 proglucagon	
fragment	 (mpgf),	 whereas	 glicentin,	 oxyntomodulin	 (oxm),	 intervening	 peptide-2	 (ip-2),	 and	 GLP-1	




body	 (figure	 4.3)	 including,	 increased	 gastric	 emptying,	 a	 decrease	 in	 appetite	 and	
importantly	for	diabetic	patients,	changes	in	glucose	control.	Glucagon-like	peptide-1	signals	
via	a	G-protein	coupled	receptor	(GPCR)	on	the	surface	membranes	of	both	α	and	β	cells	in	







Glucagon-like	peptide-1	 is	degraded	by	dipeptidyl	peptidase	4	 (DPP-4)	 in	 the	blood	stream	
(Neumiller,	2008).	DPP-4	inhibitors	or	‘gliptins’	are	used	in	diabetes	to	treat	T2DM	patients	








to	 absorption	 modulation,	 GLP-1	 had	 direct	 effects	 on	 the	 metabolism	 of	 lipids	 in	 the	
adipose	tissue	(Villanueva-Penacarrillo	et	al.,	2001).	Then	you	also	consider	that	GLP-1	will	
modulate	 the	 levels	 of	 glucagon	 and	 insulin,	 it	 is	 highly	 likely	 that	 GLP-1	 will	 also	 exert	
effects	on	the	serum	lipid	levels	indirectly	via	these	hormones.	
	
The	 part	 that	 inflammation	 plays	 in	 diabetes	 is	 partly	 linked	 to	 regulation	 of	 metabolic	
hormones	 as	 shown	 by	 recent	 studies	 by	 Kahles	 et	 al.,	 (2014).	 Glucagon-like	 peptide-1	
secretion	 is	elevated	with	 IL-6	stimulation	of	 the	 intestinal	L-cells,	which	are	considered	to	
be	 its	primary	source	(Kahles	et	al.,	2014).	 IL-6	elicits	 its	effects	on	the	cell	via	 its	receptor	




activated	 in	 the	 kidney	 to	 find	 the	best	 conditions	under	which	 it	 can	be	 inhibited.	 It	was	
then	 aimed	 at	 recreating,	 pre-clinically,	 the	 conditions	 of	 a	 phase-II	 clinical	 trial	 using	 a	
Jak1/3	inhibitor	in	DN.	It	was	also	noted	during	the	assessment	of	diabetic	mice	for	DN	that	
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there	 was	 a	 change	 in	 the	 lipid	 profile	 of	 the	 mice	 treated	 with	 the	 Jak	 inhibitor,	 these	
findings	 therefore	warranted	 further	 investigation.	 In	 this	 chapter	 data	 and	 findings	 from	








C57BL/6J	mice	 were	 obtained	 from	 Charles	 River	 UK	 Ltd.	 (Margate,	 Kent)	 at	 9wk	 of	 age.	
Mice	were	housed	with	food	and	water	ad	libitum	under	regulations	and	guidance	set	down	
in	 the	 Animals	 (Scientific	 Procedures)	 Act	 1986.	 Mice	 were	 injected	 i.p.	 with	 cocktail	 of	
lipopolysaccharide	 (LPS)	and	peptidoglycan	 (PepG)	at	a	dose	of	9/1mg/kg	 respectively	and	




C57BL/6J	 mice	 obtained	 from	 Charles	 River	 UK	 Ltd.	 (Margate,	 Kent)	 at	 9wk	 of	 age.	Mice	
were	housed	with	food	and	water	ad	libitum	under	regulations	and	guidance	set	down	in	the	
Animals	(Scientific	Procedures)	Act	1986.	All	surgery	was	carried	out	under	sterile	conditions	
body	 temperature	was	maintained	 at	 37°C	 using	 a	 homoeothermic	mat	 and	 temperature	
monitor.	Mice	were	anaesthetised	using	isoflurane,	hair	removed	by	hair	removal	cream	and	
injected	with	0.3mg/kg	buprenorphine	s.c.	once	full	anaesthesia	was	achieved.	A	full	midline	
laparotomy	was	performed	and	 the	kidneys	exposed.	The	 right	urethra	was	 isolated	using	
microdissecting	 forceps	 and	 occluded	 using	 mersilk	 suture	 twice,	 once	 proximally	 to	 the	
kidney	 and	 once	 distally,	 the	 abdominal	 cavity	 was	 closed	 using	 3-0	 proline	 suture.	Mice	
were	 recovered	 and	 returned	 to	 their	 cages	with	water	 and	 food	ad	 libitum.	 7	 days	 after	
















3. Baricitinib:	 Housed	 with	 access	 to	 HFD	 (AIN-76A	 w/58%	 fat	 energy/sucrose/red)	





once	a	week	 to	monitor	health	 and	appetite.	At	 completion	of	 the	 study	 after	 14wk	 total	
mice	 were	 sacrificed	 by	 overdose	 of	 Ketamine/Xylazine	 and	 exsanguinated	 by	 cardiac	
puncture	before	organs	were	collected	 for	analysis.	Blood	collected	 form	cardiac	puncture	
was	 then	 spun	 at	 3000g,	 serum	 was	 collected	 and	 stored	 at	 -80°C	 in	 aliquots	 for	 later	


































Tissue	 for	 analysis	 was	 lysed	 using	 ice-cold	 RIPA	 buffer	 with	 protease	 and	 phosphatase	
inhibitors	in	a	bead	lyser.	Tissue	concentrations	of	analyte	were	normalised	for	total	protein	






or	mouse	 total	 insulin/glucagon/GLP-1)	 from	MSD	 LLC.	 (Rockville,	MD,	USA)	 following	 the	




Histology	 was	 carried	 out	 on	 using	 sections	 of	 snap	 frozen	 tissue.	 Tissues	 were	 briefly	
thawed	and	fixed	using	Neutral	Buffered	Formalin	then	stained	using	oil-red-O.	Tissues	were	
differentiated	 using	 Isopropyl	 alcohol	 and	 counterstained	 using	 Mayer’s	 Haematoxylin	










cDNA	 synthesis	 for	 analysis	 by	 q-PCR	 was	 carried	 out	 using	 QuantiTect®	 Reverse	





cDNA	 samples	 synthesised	 from	 RNA	 samples	 from	 mouse	 organs	 were	 tested	 in	 q-PCR	
reactions.	These	reactions	were	set	up	 in	96-well	plates	using	TaqMan®	Fast	universal	PCR	
master	 mix	 (ThermoFisher,	 MA,	 USA).	 Probes	 were	 VIC-labelled,	 MGB-quenched	 GAPDH	
probe	 for	 control	 housekeeping	 gene	 and	 FAM-labelled,	 MGB-quenched	 gene	 of	 interest	
probes.	Protocol	was	run	using	One	Step	Plus	q-PCR	machine	from	Applied	Biosystems	and	




Pre-loaded	 RT²	 Profiler™	 PCR	 Array	Mouse	 JAK	 /	 STAT	 Signaling	 Pathway	 384-well	 Plates	
from	Qiagen	(Hilden,	Germany)	were	used	with	SYBR	Green	reagents.	This	data	was	anlysed	












value	 of	 ≤0.05	was	 considered	 to	 be	 significant.	 Also	 used	was	 two-way	 RM-ANOVA	with	









STAT1	 (figure	4.4.A),	STAT2	 (figure	4.4.B)	and	STAT3	 (figure	4.4.C)	were	all	elevated	 in	 the	















(figure	 4.5.A),	 SOCS2	 (figure	 4.5.B)	 and	 SOCS3	 (figure	 4.5.C)	 all	 showed	 an	 increase	 in	













vehicle	 and	 baricitinib	 groups	 versus	 chow.	 Total	 cholesterol	 and	 HDL	 were	 found	 to	 be	





























Serum	 insulin	 (figure	 4.8.A)	 was	 significantly	 elevated	 in	 vehicle	 and	 baricitinib	 groups	
against	chow,	with	no	significant	differences	 found	between	vehicle	and	baricitinib.	Serum	
glucagon	 (figure	 4.8.B)	 is	 significantly	 higher	 in	 baricitinib	 animals	 versus	 both	 chow	 and	





glucagon	 (B)	 along	with	 those	 of	 the	 gut	 incretin,	 GLP-1	 (C)	 for	 animals	 fed	 HFD	 and	 treated	with	



















Random	 blood	 glucose	 measurements	 from	 the	 end	 of	 the	 study	 show	 that	 there	 is	 a	
significant	increase	in	the	blood	glucose	of	vehicle	mice	against	chow.	A	decrease	in	this	was	
observed	 in	 baricitinib	mice	 versus	 vehicle,	 but	 which	 was	 just	 non-significant,	 baricitinib	
remained	non-significant	against	chow.	
	
Figure	4.10.	Data	 for	a	 random	blood	glucose	measurement	at	 termination	of	animals	 fed	HFD	and	











in	 the	amount	of	 food	eaten	by	mice	 in	vehicle	and	baricitinib	groups	but	 that	 it	was	only	
significant	against	chow	in	the	baricitinib	group.	Calorific	intake	(figure	4.11.B)	was	found	to	
be	significantly	higher	in	vehicle	and	baricitinib	groups	versus	chow	at	a	number	of	points	in	
the	study,	when	this	was	not	significant	 it	was	still	above	 the	chow	 level	 throughout.	AUC	




Figure	4.11.	 Food	 (A)	 and	energy	 (B)	 intake	data	 and	analysis	 of	 animals	 fed	HFD	and	 treated	with	
vehicle	 or	 baricitinib	 (10mg/kg)	 or	 those	 fed	 chow	 diet.	 Also,	 AUC	 analysis	 data	 for	 food	 (C)	 and	
energy	 (D)	 intake.	★	P≤0.05	 vs.	 chow	when	 analysed	 by	 one-way	 ANOVA.	 *	 P≤0.05	 baricitinib	 vs.	
chow	when	analysed	by	two-way	RM-ANOVA.	§	P≤0.05	vehicle	vs.	chow	when	analysed	by	two-way	













Figure	4.12.	Weight	progression	over	 the	12-week	HFD	study	 for	animals	 fed	HFD	and	 treated	with	
vehicle	or	baricitinib	 (10mg/kg)	or	 those	 fed	chow	diet.	★	P≤0.05	vs.	 chow	when	analysed	by	one-
way	ANOVA.	*	P≤0.05	vehicle	vs.	chow	when	analysed	by	two-way	RM-ANOVA.	§	P≤0.05	baricitinib	



























Analysis	 of	 the	 data	 from	 MRI	 scans	 is	 displayed	 in	 figure	 4.14,	 this	 data	 relates	 to	 the	
images	 shown	 in	 figure	 4.13.	Quadriceps	muscles	 in	 animals	 in	 the	 vehicle	 and	 baricitinib	
groups	 show	 a	 significant	 increase	 in	 their	 proportional	 fat	 content	 compared	 to	 chow	
animals.	Baricitinib	animals	displayed	a	 significantly	 lower	 level	of	 fat	 compared	 to	vehicle	
but	this	was	still	significantly	higher	than	that	seen	in	chow	animals.	
	
Figure	 4.14.	 Representative	 images	 and	 volumetric	 analysis	 of	 perimuscular	 fat	 in	 the	 quadriceps	
muscles	of	animals	fed	HFD	and	treated	with	vehicle	or	baricitinib	(10mg/kg)	or	those	fed	chow	diet.	






IL-10	 (figure	 4.15.A)	 was	 significantly	 elevated	 in	 baricitinib	 mice	 versus	 both	 chow	 and	
vehicle	mice	with	 no	 change	 between	 chow	 and	 vehicle	 groups.	 IL-1β	 (figure	 4.15.B)	was	
significantly	elevated	 in	vehicle	mice	versus	both	chow	and	baricitinib	with	no	significance	
between	 chow	 and	 baricitinib.	 IL-6	 (figure	 4.15.C)	 was	 significantly	 higher	 in	 vehicle	mice	























The	 most	 striking	 result	 of	 these	 investigations	 was	 in	 fact	 an	 accidental	 discovery.	 The	







the	actual	diabetes	disease	state	by	reducing	 insulin	resistance	 it	would	be	 logical	 to	think	
that	in	this	case,	the	disease	is	 less	severe	therefore	this	justifies	the	change	in	lipid	levels.	
None	of	 the	evidence	presented	here	 in	 this	 thesis	 suggests	 that	baricitinib	has	 in	anyway	
improved	the	disease	state	of	these	animals.	The	random	glucose	measurements	show	that	
glucose	is	still	elevated	against	chow,	albeit	not	significantly.	This	paired	with	the	data	from	




the	 abolition	 of	 GLP-1	 signalling	 in	 the	 serum.	 GLP-1	 has	 little	 direct	 effect	 on	 glucose	
metabolism	 rather	 mediating	 their	 effects	 via	 modification	 of	 pancreatic	 α	 and	 β-cells	
(Baggio	&	Drucker,	 2007).	 So,	 the	 effects	 of	 this	 vast	 reduction	 in	GLP-1	 in	 the	 serum	are	
noticeable	in	the	modulation	of	insulin	and	glucagon.	Our	result	show	the	expected	changes	
in	 these	 hormones	 associated	 with	 drops	 in	 GLP-1	 levels;	 reduced	 (mildly)	 insulin	 and	




is	 going	 to	 increase	 the	 uptake	 and	 metabolism	 of	 all	 fats,	 withdrawing	 them	 from	 the	
circulation	 (Aydin	 &	 Sokal,	 1963).	 Indeed,	 recent	 studies	 have	 shown	 that	 incubating	
hepatocytes	with	glucagon	reduces	the	activity	of	SREBP	genes	(Horton,	Goldstein	&	Brown,	
2002)	which	are	 involved	 in	cholesterol	synthesis,	meaning	that	there	 is	 less	production	of	
cholesterol	 in	the	liver	and	so	lower	circulating	cholesterol.	The	most	recent	studies	 in	this	
area	 show	 that	 there	 is	 a	 direct	 effect	 of	 hypergulcagonaemia	 on	 lowering	 hepatic	
generation	 of	 VLDL	 and	 LDL	 in	 humans,	 proving	 the	 cholesterol	 lowering	 effects	 of	 acute	
glucagon	increases	in	lowering	serum	cholesterol	(Changting	et	al.,	2011).	This	study	showed	
that	in	humans	subjected	to	a	3-fold	increase	in	glucagon	had	a	significant	reduction	in	LD.	In	




The	 changes	 in	 GLP-1	 do	 not	 seem	 to	 influence	 the	 diabetic	 condition;	 the	 very	 mild	
reduction	 in	 insulin	 levels	 is	 not	 significant	 against	 vehicle	 and	 remains	 significant	 against	
chow	 fed	mice.	 Blood	 glucose	 remains	 non-significant	 in	 its	 changes	 between	 vehicle	 and	
baricitinib	groups	and	hunger	 is	unchanged	between	HDF	groups,	 the	changes	observed	 in	




source	 of	 fatty	 acids.	 Inflammation	 within	 adipose	 tissue	 has	 for	 a	 long	 time	 been	





increase	 in	 serum	 lipids	 (Van	Gaal,	Mertens	&	Christophe,	 2006).	 Adipose	 inflammation	 is	
thought	to	lead	to	fat-remodelling	and	deposition	of	lipid	in	muscles	(Khan	et	al.,	2015)	and	
vascular	 tissues	 (O’Keefe	 &	 Bell,	 2007)	 leading	 to	 complications	 like	 CVD	 and	 increased	
insulin	resistance.	Our	findings	show	that	there	is	a	decrease	in	not	only	the	inflammation	of	




IL-6	 is	 thought	 to	be	one	of	 the	key	mediators	of	diabetic	adipose	 inflammation	 (Sultan	et	




2011)	so	a	decrease	 in	 IL-6	would	 logically	reduce	GLP-1	production	from	intestinal	L-cells.	
However,	 there	may	be	another	mechanism	at	play	related	to	the	 IL-6/GLP-1	axis,	 the	 IL-6	
receptor	associates	with	Jak/STAT	proteins	(Stahl	et	al.,	1994)	in	order	to	induce	changes	in	
its	target	cells.	The	blockade	of	the	Jak/STAT	pathway	in	IL-6	signalling	would	mean	that	IL-6	
mediated	 GLP-1	 release	 would	 be	 inhibited.	 Our	 results	 show	 that	 there	 is	 an	 enormous	
activation	of	the	Jak/STAT	pathway	in	conditions	that	are	heavily	linked	to	IL-6;	this	is	shown	
by	the	upregulation	of	Jak/STAT	associated	genes	in	LPS	challenged	mice.	LPS	administration	
models	 the	 human	 condition	 sepsis,	 which	 is	 known	 to	 have	 a	 strong	 link	 to	 IL-6	 release	
(Riedemann	et	al.,	2003).	
	
It	 could	 be	 that	 what	 is	 happening	 here	 is,	 rather	 than	 a	 return	 to	 normal	 signalling,	 or	
abrogation	 of	 adipose	 inflammation,	 Jak/STAT	 inhibition	 is	 inducing	 physiological	 changes	










modulation	 of	 circulating	 triglycerides	 casts	 doubt	 on	 this	 conclusion.	 It	means	 that	 there	





result	 of	 hepatotoxicity.	 Our	 results	 see	 that	 there	 is	 an	 apparent	 increase	 in	 the	 hepatic	
storage	of	lipid,	which	is	associated	with	cirrhosis	(Farrell	&	Larter,	2006)	and	there	is	also	a	
reduction	in	serum	albumin,	which	is	again,	potentially	indicative	of	liver	damage	(Reilly		et	
al.,	 1990).	 It	 should	 also	 be	 highlighted	 that	 previous	 Jak	 inhibitors	 have	 been	 found	 to	
induce	 hyperlipidaemia	 in	 patients	 taking	 them	 for	 RA	 (Kontzias	 et	 al.,	 2012)	 so	 these	












has	 long	been	 thought	 that	 there	 is	 a	 link	between	 the	 clinical	 conditions	of	diabetes	and	
natural	ageing	(Mbanya,	2012)	and	they	constitute	a	heavy	burden	on	healthcare	systems.	
There	 is	 currently	 no	 ‘magic	 bullet’	 treatment	 for	 diabetes	 and,	 therefore,	 patients	 with	
diabetes	are	often	some	of	the	most	heavily	medicated	patients	in	hospital	and	community	
care	(Peron,	Ogbonna	&	Donohoe,	2015).	These	drugs	are	leading	to	a	population	of	diabetic	
patients	 that	 are	 living	 increasingly	 long	 lives,	 combining	 their	 diabetic	 condition	with	 the	
complications	 of	 natural	 ageing,	 leading	 to	 polypharmacy	 in	 these	 patients	 (Good,	 2002).	
With	every	new	drug	 that	 is	 added	 to	an	ageing	patient	 the	 risk	of	drug-drug	 interactions	
and	negative	 reactions	 increases	 (Gorard,	2006).	There	 is	now	a	 call	 for	 treatments	aimed	
towards	treating	the	condition	or	at	least	ones	that	will	have	a	positive	effect	on	many	of	the	
linked	 pathologies.	 This	 thesis	 has	 attempted	 to	 assess	 the	 possibility	 that	 baricitinib	 is	 a	
step	closer	to	finding	a	drug	that	can	treat	multiple	pathologies	associated	with	DM.	
	
The	 first	conclusion	 to	make	 is	 that	 the	oral	DGal	model	of	advancing	age,	 is	 indeed	not	a	
model	of	advanced	age	at	all.	This	model	has	been	shown	here	to	not	be	linked	to	ageing	in	
the	general	 viscera	but	 in	 the	brain	alone.	Though	 the	model	has	been	used	previously	 to	
stimulate	 ageing	 in	 the	 renal	 tissues	 (Aydin	 et	 al.,	 2012),	 our	 model	 showed	 that	 these	
results	may	be	flawed.	It	could	be	that	the	difference	in	route	of	administration	(oral	versus	
i.p.)	 resulted	 in	 a	 lower	 plasma	 concentration	 of	 DGal	 that	 was	 high	 enough	 to	 result	 in	
changes	in	the	brain	but	not	in	the	kidney.	It	may	also	be	that	organs	such	as	the	kidney	and	
the	 liver,	where	we	studied,	are	more	resistant	to	this	 insult	 than	organs	 like	the	brain,	so	
injury	was	still	caused	but	at	a	level	below	that	which	we	could	measure.	Finally,	it	could	be	
argued	that	we	did	not	dose	these	animals	for	long	enough	for	the	effect	to	be	seen	in	the	








Our	 investigations	 into	baricitinib	have	 shown	clearly	one	 thing	above	all,	 and	 that	 is	 that	
baricitinib	 is	 not	 a	 drug	 that	 can	 improve	 insulin	 sensitivity	 and	 ‘roll	 back	 the	 clock’	 on	
diabetes.	We	should	not	see	this	drug	as	the	‘magic	bullet’	as	it	has	no	effect	on	the	diabetic	
condition	 itself	under	our	conditions.	Hyperglycaemia	 is	still	 the	most	prominent	symptom	
of	 diabetes	 and	 needs	 to	 be	 treated	 at	 the	 earliest	 stages	 of	 the	 disease	where	 possible,	
drugs	like	the	anti-hyperglycaemic	metformin	and	the	DPP-4	inhibitor	sitagliptin	continue	to	
show	 clinical	 efficacy	 and	 remain	 the	 first	 line	 treatments	 for	 diabetes	 for	 good	 reason	
(Aschner	et	al.,	2006,	Klepser	&	Kelly,	1997,	NICE	2016).	
	
DN	 is	 currently	 treated	 with	 angiotensin-converting	 enzyme	 (ACE)	 inhibitors	 for	 the	
underlying	 hypertension	 that	 can	 lead	 to	 DN	 and	 worsen	 it.	 This	 method	 of	 treatment	






My	 findings	 regarding	 baricitinib	 are	 like	 those	 found	 relating	 to	 the	 anti-diabetic	 drug	
troglitazone	 which	 was	 found	 to	 prevent	 mesangial	 expansion	 (McCarthy	 et	 al.,	 2000).	
troglitazone	 is	an	anti-diabetic	drug	of	the	class	glitazones	(thiazolidinediones),	 it	mediates	
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its	 effects	 by	 acting	 as	 a	 ligand	 the	 peroxisome	 proliferator	 activated	 receptor-γ	 (PPARγ).	
PPARγ	is	one	of	three	nuclear	sensors	of	fatty	acid	concentration	which	act	as	transcriptional	
activators,	the	others	being,	PPARα	and	PPARδ.	Glitazones	act	to	increase	insulin	sensitivity	
in	multiple	 tissue	 types;	 these	 include	adipose,	 liver	and	 skeletal	muscle.	 In	muscle	 tissue,	
uptake	of	glucose	is	promoted	by	increased	PPARγ	activity	resulting	in	higher	expression	of	
GLUT-1	 allowing	 increased	 flux	 of	 glucose	 into	 the	 cell	 (Zierath	 et	 al.,	 1998).	 Increased	
glucose	 in	myocytes	 is	 followed	 by	 heightened	 activity	 of	 Glucose-6-Phosphate	 (G6P)	 and	
higher	rates	of	glycogen	synthesis	(Petersen	et	al.,	2000).	In	adipose	a	similar	increase	in	not	
only	 GLUT-1,	 but	 also	 GLUT-4	 (Sandouk,	 Reda	 &	 Hofmann,	 1993)	 is	 observed	 under	 the	
action	 of	 glitazones	 followed	 by	 a	 decrease	 in	 lipolysis	 and	 promotion	 of	 lipogenesis	
(Gastaldelli	et	al.,	2009).	Finally,	in	hepatocytes,	GLUT-2	is	upregulated	under	application	of	
glitazones	 (Smith,	2002)	with	decreased	glycogenolysis,	one	of	 the	key	actions	of	 the	 liver	
under	insulin	stimulation	(Miyazaki	et	al.,	2001).	
	
Glitazones	 have	 a	 positive	 effect,	 as	 might	 be	 expected	 given	 their	 mode	 of	 action,	 on	
glucose	 tolerance	 (DeFronzo	et	 al.,	 2011)	 and	 insulin	 tolerance	 (Nolan	et	 al.,	 1994).	 These	










lipids	 (Gastaldelli	 et	 al.,	 2009).	 The	putative	mechanism	 for	 this	 is	 that	 there	 is	 a	 reduced	
‘flux’	of	 lipids	 from	adipose	 tissue	 to	 liver	 and	an	associated	decrease	 in	ApoB	production	
meaning	 that	 lipoproteins	become	 increasingly	dense	 (Seedorf	&	Aberle,	2007).	 Figure	5.2	
shows	the	effects	of	PPAR’s	on	the	 flux	 lipids	between	adipose	and	hepatic	 tissues,	where	












that	 the	 interactions	 of	 PPARγ	 agonists	 promoted	 necrotic	 and	 apoptotic	 processed	 in	
hepatocytes	leading	to	liver	damage	(Guo	et	al.,	2006).	
	
The	 work	 of	 McCarthy	 et	 al.,	 (2000)	 suggests	 that	 the	 activation	 of	 PPARγ	 prevents	
mesangial	 expansion	 due	 to	 increased	 glycaemic	 control.	 Their	 results,	 in	 terms	 of	
reductions	 in	 mesangial	 expansion	 and	 urinary	 ACR	 were	 like	 those	 presented	 here.	 Our	
results	go	deeper	than	theirs	 into	the	mechanistic	background	of	our	drug.	 	Given	the	fact	
that	baricitinib	does	not	have	any	effect	on	insulin	or	glucose	sensitivity	and	yet	there	is	an	
improvement	 in	 mesangial	 expansion,	 it	 seems	 unlikely	 that	 the	 reduced	 mesangial	
expansion	is	due	to	increased	glycaemic	control.	
	
The	overall	 picture	of	 baricitinib	 in	HFD	and	diabetes	 looks	 rather	 similar	 to	 that	 of	many	
glitazones,	like	troglitazone.	Lowering	of	serum	lipids,	especially	cholesterol	and	preventing	
mesangial	 expansion	 are	 found	 both	 with	 some	 glitazones	 and	 baricitinib	 in	 our	
experiments.	However,	 there	 is	 a	 glaring	difference	 in	 the	effects	 of	 these	 two	drugs,	 our	





only	 increases	SOCS3	expression	which	has	 long	been	known	to	 inhibit	 Jak/STAT	activation	
but	also	that	it	directly	inhibits	STAT3.	Figure	5.3.A	shows	the	process	of	negative	feedback	
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by	 SOCS	 on	 cytokine	 induced	 STAT	 translocation	 and	 transcription,	 whereby	
unphosphorylated	 Jak	 is	 targeted	 for	 proteosomal	 degradation.	 Similar	 effects	 of	 PPARγ	
have	 been	 found	 and	 a	 representation	 of	 this	 is	 seen	 in	 figure	 5.3.B	 where	 STAT	
translocation	is	prevented	by	inhibition	of	both	Jak	and	STAT	by	activated	PPARγ.	
	
Figure	 5.3.	A,	 SOCS	 inhibition	of	 JAK/STAT	 signalling	 that	 results	 in	 proteasomal	 degradation	of	 Jak	
and	abrogation	of	Jak/STAT	Signalling	(adapted	from	Andò	&	Catalano,	2012).	B,	a	similar	pathway	to	







not	 mention	 the	 induction	 of	 cell	 cycle	 arrest	 or	 induction	 of	 apoptosis	 but	 the	 work	 of	
Okada	et	al.,	(2006)	specifically	implicates	pioglitazone	in	cell	cycle	arrest	in	amelioration	of	
DN.	 Okada	 et	 al.,	 (2006)	 specifically	 implicates	 increased	 p21cip1/waf1	 expression	 in	 this	
process,	 providing	 a	 very	 strong	 link	 between	 the	 mode	 of	 actions	 of	 baricitinib	 and	





the	 known	 effects	 of	 glitazones	 lead	 me	 to	 postulate	 that	 there	 is	 a	 uniting	 factor.	 The	
antagonistic	effects	of	activated	PPARγ	on	 Jak/STAT	activation	observed	by	Yu,	Kim	&	Kim	
(2008)	 coupled	 with	 known	 effects	 of	 SOCS	 on	 Jak/STAT	 activation	 (Yoshimura,	 Naka	 &	
Kubo,	2007)	lead	to	the	conclusion	that	STAT	acts	antagonistically	to	PPARγ.	In	this	thesis,	it	
has	 been	 shown	 that	 Jak/STAT	 inhibition	 is	 associated	 with	 a	 reduction	 in	 glomerular	
hypertrophy	similar	to	that	shown	by	glitazones	therapy.	
	
The	 lack	 of	 insulin	 sensitisation	 in	 mice	 treated	 with	 baricitinib	 leads	 me	 to	 suggest	 the	
theory	that	STAT	antagonises	the	action	of	activated	PPARγ	with	respect	to	lipid	metabolism	









The	profile	 of	 animals	 on	HFD	 treated	with	baricitinib	 is	 strikingly	 similar	 to	 that	 that	 one	
would	 expect	 of	 one	 treated	with	 a	 glitazone.	 Our	mice	 lacked	 sensitisation	 to	 insulin	 or	
glucose	which	would	 be	 expected	 of	 animals	 on	 a	 glitazone,	 this	 leads	 us	 to	 believe	 that	
Jak/STAT	 inhibition	 results	 in	 a	 lowering	 of	 lipid	 profiles	 and	 reduction	 in	 mesangial	
expansion	by	a	similar	mechanism	to	that	of	PPARγ	activation	but	 that	 it	has	a	sub-clinical	
effect	 on	 glucose	metabolism.	Our	 results	 are	not	 conclusive	on	whether	 there	 is	 a	 direct	
mechanistic	 link	 between	 STAT	 and	PPARγ	 activation	 but	 current	 literature	would	 suggest	
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There	 is	 currently	one	FDA	approved	PPARγ	agonists	on	 the	market	after	 troglitazone	was	
withdrawn	 in	2000	due	to	safety	concerns	over	cardiac	and	hepatic	affects.	Pioglitazone	 is	
used	commonly	 in	combination	with	metformin	for	the	treatment	of	diabetes	(NICE,	2016)	
with	 other	 PPAR	 agonists	 in	 development	 for	 obesity	 and	 dyslipidaemia.	 There	 are	 still	
concerns	 over	 the	 safety	 of	 PPARγ	 activators	 regarding	 their	 safety	 (Balakumar	 &	









2014)	 though	 it	 has	 been	 discussed	 earlier	 in	 this	 thesis	 that	 the	 doses	 used	 in	 current	
clinical	trials	are	vastly	lower	than	those	used	in	our	experiments.	In	terms	of	the	reaction	of	





effects	 that	 may	 be	 mechanistically	 linked	 it	 would	 be	 important	 to	 keep	 in	 mind	 the	
possibility	that	baricitinib,	at	doses	similar	to	those	presented	here,	would	result	in	the	same	
adverse	 effects	 as	 seen	with	 glitazones.	 It	 seems	 that	 there	 is	 very	 little	 difference	 in	 the	













Inflammation	 related	 to	 ageing	 may	 well	 have	 a	 part	 to	 play	 in	 the	 damage	 to	 nutrient	
sensing	 in	 ageing	 and	 therefore	 potential	 predisposition	 to	 diabetes.	 Baricitinib	 showed	
scant	anti-inflammatory	properties,	except	 in	TNFα	and	had	 little	effect	on	 the	key	ageing	
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related	 cytokines,	 KC	 and	 IL-1β.	 The	 effects	 of	 baricitinib	 do	 not	 match	 up	 with	 the	
proinflammatory	 ageing	 phenotype	 that	 was	 found	 in	 chapter	 II.	 This	 lack	 of	 anti-
inflammatory	action	means	 that	baricitinib	would	 likely	have	 little	effect	on	 inflammaging,	
but	 its	organ	protective	effects	 could	 still	be	mediated	by	other	means	and	could	warrant	
further	exploration.	
	
The	 effects	 of	 ageing	 on	 renal	 anatomy,	 including	 glomerular	 hypertrophy	 and	 capsule	
expansion	shown	in	chapter	II	are	similar	to	that	shown	in	chapter	III.	This	could	contribute	
to	the	worsening	of	DN	in	elderly	patients	and	given	the	similarity	in	morphology	could	be	as	




DN.	 	 Both	 PPARγ	 activators	 and	 jakinibs	 could	 prove	 a	 useful	 clinical	 drug	 in	 treating	 the	
effects	 of	 diabetes	 and	 as	 a	 prophylactic	 drug	 for	 nephropathy.	 This	 could	 be	 particularly	
applicable	for	elderly	patients	on	long-term	treatment	for	DM	or	RA	meaning	that	they	are	


















§ Increased	 tissue	 and	 circulating	 KC	 along	with	 changes	 throughout	
the	body	in	levels	of	IL-1β	and	other	key	cytokines.	

















in	 DN.	 Firstly,	 baricitinib’s	 effects	 in	 DN	 have	 already	 been	 shown	 in	 human	 trials	 so	 its	








oral	 Jak1/3	 inhibitor,	 tofacitinib	 from	 Pfizer	 (Garber,	 2013),	 this	 drug	 would	 likely	 be	
expected	to	have	similar	effects	to	that	of	baricitinib	given	similarities	of	the	pathways	they	
both	 inhibit	and	 its	proposed	mode	of	action	 in	RA.	Other	similar	kinase	 inhibitors	such	as	
AG490	have	been	used	 in	both	 in	vitro	 (Wang	et	al.,	2002)	and	 in	vivo	 (Banes	et	al.,	2004)	
models	of	DN	and	have	shown	some	interesting	results	similar	to	those	seen	in	this	thesis.	
	
Clinical	 comparisons	must	be	made	using	existing	 treatments	 for	DN.	Both	pre-clinical	and	
clinical	head-to-head	comparisons	of	baricitinib	and	ACE-inhibitors	would	potentially	 show	
the	 differences	 in	 mechanism	 by	 clinical	 effect.	 If	 baricitinib	 does	 in	 fact,	 as	 this	 thesis	





The	 final	 and	 potentially	most	 important	 future	 extension	 to	 this	 programme	 of	 study	 to	
confirm	the	findings	would	be	to	attempt	to	replicate	these	results	at	a	more	physiological	





of	 baricitinib	 and	 how	 it	 has	 come	 about	 in	 this	 model.	 Given	 the	 current	 evidence	 that	
baricitinib	 (Tanaka	 et	 al.,	 2016)	 and	 tofacitinib	 (Burmester	 et	 al.,	 2013)	 induce	
hypercholesterolaemia	 and	 data	 from	 phase	 II	 trials	 show	 a	 dose-dependent	 elevation	 in	
total	cholesterol	 levels	 (Kremer,	2016),	 it	 is	 important	that	this	result	 is	developed	further.	
The	lipid-lowering	effects	of	this	drug	could	first	be	evaluated	by	administering	it	to	animals	
on	a	chow	diet	to	look	for	sub-normal	depletion	of	cholesterol,	as	the	proposed	mechanism	
of	 this	effect	may	be	unrelated	to	the	 induction	of	diabetes.	Also	of	 interest	would	be	the	
use	of	another	model	of	hyperlipidaemia,	such	as	a	genetic	model	like	that	of	the	Watanabe	




in	 vivo	 work	 on	 this	 drug	 in	 hyperlipidaemic	 animals	 would	 yield	 a	 great	 amount	 of	





Head-to-head	 trials	 of	 baricitinib	 and	 glitazones	 are	 essential	 for	 the	 conformation	 of	 the	
mimetic	 effects	 seen	 in	 this	 study.	 Control	 studies,	 using	 both	 drugs	 under	 identical	




impairment	 in	 these	animals.	Before	any	 future	human	 trials	using	 this	drug	at	equivalent	
doses	to	this	study	could	be	initiated	proper	and	full	pre-clinical	evaluations	of	the	hepatic	
implications	 of	 its	 use	 would	 need	 to	 be	 published.	 Pre-clinical	 evaluation	 of	 the	 drug	
showed	 efficacy	 using	 doses	 equivalent	 to	 ours	 (Fridman	 et	 al.,	 2010)	 and	 other	 studies	
(Khan	 et	 al.,	 2015)	 have	 also	 used	 10mg/kg	 in	 mouse	 and	 rat	 studies	 with	 no	 reported	






Without	doubt	 the	negative	effects	of	 baricitinib	on	 the	elderly	 are	 important	 to	 consider	
and	 further	 work	 based	 on	 Fleischmann	 et	 al.,	 (2016)	 is	 needed	 with	 higher	 doses	 that	
appear	 to	be	therapeutic	 in	DN.	More	than	this	 though	 it	 is	 important	 that	we	 look	at	 the	
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